



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Multimodal Mapping of Electrical and Mechanical Latency of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Layers

This is the peer reviewed version of the following article:

Original

Multimodal Mapping of Electrical and Mechanical Latency of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Layers / Zhang, X.; Burattini, M.; Duru, J.; Chala, N.; Wyssen, N.; Cofino-Fabres, C.; Rivera-Arbelaez, J. M.; Passier, R.; Poulidakos, D.; Ferrari, A.; Tringides, C.; Voros, J.; Luciani, G. B.; Miragoli, M.; Zambelli, T.. - In: ACS NANO. - ISSN 1936-0851. - 18:35(2024). [10.1021/acsnano.4c03896]

Availability:

This version is available at: 11381/3000042 since: 2024-09-12T10:55:06Z

Publisher:

American Chemical Society

Published

DOI:10.1021/acsnano.4c03896

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverage

(Article begins on next page)

02 May 2026

Multimodal Mapping of Electrical and Mechanical Latency of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Layers

Xinyu Zhang, Margherita Burattini, Jens Duru, Nafsika Chala, Nino Wyssen, Carla Cofino Fabres, Jose Manuel Rivera Arbelaez, Robert Passier, Dimos Poulikakos, Aldo Ferrari, Christina Tringides, János Vörös, Giovanni Battista Luciani, Michele Miragoli,* and Tomaso Zambelli*



Cite This: <https://doi.org/10.1021/acsnano.4c03896>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: The synchronization of the electrical and mechanical coupling assures the physiological pump function of the heart, but life-threatening pathologies may jeopardize this equilibrium. Recently, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as a model for personalized investigation because they can recapitulate human diseased traits, such as compromised electrical capacity or mechanical circuit disruption. This research avails the model of hiPSC-CMs and showcases innovative techniques to study the electrical and mechanical properties as well as their modulation due to inherited cardiomyopathies. In this work, hiPSC-CMs carrying either Brugada syndrome (BRU) or dilated cardiomyopathy (DCM), were organized in a bilayer configuration to first validate the experimental methods and second mimic the physiological environment. High-density CMOS-based microelectrode arrays (HD-MEA) have been employed to study the electrical activity. Furthermore, mechanical function was investigated via quantitative video-based evaluation, upon stimulation with a β -adrenergic agonist. This study introduces two experimental methods. First, high-throughput mechanical measurements in the hiPSC-CM layers (*xy*-inspection) are obtained using both a recently developed optical tracker (OPT) and confocal reference-free traction force microscopy (cTFM) aimed to quantify cardiac kinematics. Second, atomic force microscopy (AFM) with FluidFM probes, combined with the *xy*-inspection methods, supplemented a three-dimensional understanding of cell–cell mechanical coupling (*xyz*-inspection). This particular combination represents a multi-technique approach to detecting electrical and mechanical latency among the cell layers, examining differences and possible implications following inherited cardiomyopathies. It can not only detect disease characteristics in the proposed *in vitro* model but also quantitatively assess its response to drugs, thereby demonstrating its feasibility as a scalable tool for clinical and pharmacological studies.

KEYWORDS: hiPSC-CMs, Brugada syndrome, dilated cardiomyopathy, traction force microscopy, optical tracker, HD-MEA



INTRODUCTION

Cardiovascular diseases continue to be a predominant cause of illness and mortality worldwide, using estimates from 204 countries and territories from 1990 to 2019.¹ Cardiomyocytes (CMs) are the functional building blocks of the heart and play a central role in cardiac contraction.^{2,3} Their ability to ensure coordinated contraction at the tissue level is based on highly coupled electrical and mechanical signaling, resulting in rhythmic cardiac activity.^{4,5} Any disruption in this coupling, whether due to electrical (i.e., arrhythmia, conduction block by defected ion channels (Brugada syndrome))^{6–8} or mechanical

disturbances (dilated cardiomyopathy,^{9,10} myocardial infarction¹¹), can lead to potentially life-threatening conditions.^{12,13}

Coordinated contraction begins with the transmission of electrical signals between individual CMs through key

Received: March 22, 2024

Revised: July 23, 2024

Accepted: July 29, 2024

46 conduction pathways such as gap junctions.¹⁴ Afterward, the
 47 electrical signal is converted to a mechanical contraction
 48 through a chain of biochemical cues for each CMs, known as
 49 electro-mechanical coupling.⁵ Under the regulation of electrical
 50 activity, mechanical forces appear between neighboring CMs,
 51 as well as between CMs and the extracellular matrix (ECM).
 52 Mechanical crosstalk is especially complex in CMs, as CMs
 53 sense and generate forces at the same time, this interaction
 54 between CMs and external forces is bidirectional and occurs
 55 through complex biochemical signaling pathways.¹⁵ For
 56 example, between CMs, intercalated discs are the highway
 57 through which electrical and mechanical signals flow,^{16,17} and
 58 transmembrane proteins (e.g., desmosomes, N-cadherin)
 59 mechanically link the cytoskeleton of two adjacent CMs.^{16,18}
 60 The resulting force between adjacent cells is correlated with
 61 the size of these junctions, as previous studies have shown.¹⁹
 62 Communication between the cell and the ECM is mainly
 63 through focal adhesions involving macromolecular assemblies
 64 (such as integrins and receptors), which link intracellular actin
 65 and the ECM.^{20,21} Irregularities in this machinery can occur
 66 and cause severe cardiac pathologies.^{12,13}

67 The elucidation of coordinated CMs contraction and
 68 cardiovascular disease mechanisms relies on functional studies
 69 with in vivo animal models and in vitro models. Animal models
 70 have become increasingly restricted for ethical reasons²² and
 71 do not completely recapitulate the human geno- and
 72 phenotype. In contrast, in vitro models, particularly human-
 73 induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
 74 CMs), offer an alternative approach to animal cell models.²³
 75 The application of hiPSC-CMs also provides a particular
 76 advantage in modeling cardiac diseases, they can be engineered
 77 or patient-derived disease lines,²³ providing information on
 78 cardiac diseases and variability of drug toxicity for personalized
 79 medicine.^{24–26} In this study, we employed hiPSC-CMs in a
 80 bilayer configuration as our in vitro model, which is considered
 81 more physiologically relevant compared to the single-cell
 82 studies.³ Despite its relevance, the cell–cell interaction of this
 83 configuration still lacks in-depth studies.²⁷ This knowledge gap
 84 may arise due to the complex machinery of CM contraction
 85 mentioned above, involving interactions that occur between
 86 mechanical, electrical, and biochemical cues.¹⁵ The in vitro
 87 model adopted in this work not only allows the study of
 88 contractility differences in healthy and diseased hiPSC-CMs
 89 both mechanically and electrically but also offers a
 90 considerable opportunity to investigate the interaction
 91 between hiPSC-CMs.

92 In achieving clinical relevance for pharmaceutical analysis, in
 93 addition to a carefully designed in vitro model, a validated
 94 quantification of CM contraction is also of great importance.
 95 This quantification has to address two aspects of the CM
 96 contraction measurement: the electrical action potential and
 97 mechanical contractility.

98 Electrical quantification typically relies on established
 99 electrophysiological techniques, such as patch clamps or glass
 100 microelectrode arrays (MEAs).^{28,29} Although the patch clamp
 101 generally provides information about the action potential of
 102 individual CMs, it lacks the ability to evaluate the overall
 103 electrical signal propagation within the bilayer model adopted
 104 with single-cell resolution. Recently, high-throughput electro-
 105 physiology techniques, such as glass-based or complementary
 106 metal-oxide semiconductors (CMOS)-based multielectrode
 107 arrays (MEAs) showed potential in measuring the electrical
 108 connectivity of CMs.³⁰ Glass MEAs provide spatial informa-

tion on the action potentials of a layer of CMs, but the
 recorded activity is typically the collective electrical signals of
 surrounding cells.^{28,31} In this work, we used a high-density
 CMOS-based microelectrode array (HD-MEA) platform to
 enable the recording of extracellular action potentials (ecAP)
 at the cellular level with a spatial resolution of 17.5 μm ,
 corresponding to the pitch between electrodes, and a temporal
 resolution of 0.05 ms (Figure 1).^{32–34}




Figure 1. Experimental methods to quantify the mechanical and electrical behavior of a hiPSC-CM bilayer. Mechanical quantification of the hiPSC-CM layer is separately performed with two methods: xy-inspection focuses on high throughput force analysis in the xy axis (from QD: while focusing on the basal side) with simultaneous recording of bright field (BF); xyz-inspection provides force recording of xy (from QD focusing on the basal side analyzed by cTFM), and z (from FluidFM focusing on the apical side). Electrically, the HD-MEA platform is used to record the action potential map (yellow pitch indicates the CMOS recording electrodes).

As the other part of the equation, mechanical machinery can
 be analyzed by using different approaches. Traction force
 microscopy (TFM) has been instrumental in mapping
 contractile forces generated by cells.^{35–38} Among various
 TFM techniques, particle tracking is widely used, providing
 high spatial resolution with hundreds of nanometers data with
 pN sensitivity, but it requires a reference image and lacks
 tunable lateral resolution for complex cellular systems,^{35,39}
 limiting its use to the single cell level.⁴⁰ Video microscopy-
 based TFM techniques are often employed for the evaluation
 of contractility of in vitro tissue models with multiple cell types
 or 3D CM spheroids,^{41,42} overcoming the limitations of particle
 tracking TFM. Despite their great potential for automation,
 video microscopy-based methods normally measure displace-
 ment in the range of microns, failing to evaluate the μN force
 developed by the sample. Thus, to match the displacement
 with the force measurements, calibration is needed.⁴² Confocal
 reference-free Traction Force Microscopy (cTFM) is capable
 of measuring the contractility of CMs layer^{27,43,44} with a high-
 resolution characteristic.⁴⁵ Specifically, it achieves tunable
 lateral resolution through adjustable spacing in the array and
 obtains accurate measurements without the need for a
 reference image. In this work, we calibrated a recently
 developed video microscopy method: Optical Tracker
 (OPT) with cTFM (Figure 1, Video S1). Combining them
 allowed us to measure the contractility of hiPSC-CM layers in
 2D (xy inspection, Figure 1). Furthermore, FluidFM was
 enforced to inspect and complement the xy inspection with
 vertical displacement^{46,47} (xyz inspection Figure 1).




Figure 2. Mechanical properties of hiPSC-CMs with *xy*-inspection. (a) cTFM analyzes the deformation of a quantum dot array with a spacing of 5 μm (first panel) and generates the corresponding strain map induced by the contractile forces of hiPSC-CMs (second panel). The latency is mapped spatially (third panel). (b) BF channel of recording could be analyzed by OPT_BF (first panel) with detected moving features indicated in green crosses, yielding the corresponding force map (second panel) and latency map (third panel). (c) Mean traction force profiles of corresponding methods and cTFM (orange) are compared with those of the OPTBF (blue). (d) Latency distributions of contraction features (amplitude, beat duration, and interspike time) between OPT_BF and cTFM ($N = 4$). No statistically significant difference between any measured parameters. (e) A statistical comparison of contraction features (amplitude, beat duration, and interspike time) between OPT_BF and cTFM ($N = 4$). No statistically significant difference between any measured parameters. (f) Latency distributions were integrated with different samples ($N = 4$), see details in methods TFM analysis section.

146 The cTFM technique utilizes quantum dots (CdSe) with 25
147 nm size,⁴⁸ deposited with the nanodrip platform having 100–
148 200 nm spatial resolution, while HD-MEA chips, recording
149 ecAP of hiPSC-CMs, are fabricated according to a lithography
150 process with 180 nm resolution. Additionally, the QD array is
151 detected with 400 nm/pixel resolution in the *xy*-inspection,
152 while the *xyz*-inspection provides a 100 nm/pixel resolution,
153 enabling FluidFM measurements of the hiPSC-CMs contrac-
154 tility in the *z* direction with pN sensitivity.

155 The objective of this study was to quantitatively characterize
156 the hiPSC-CM bilayer electrically and mechanically using the
157 presented platforms. Moreover, with the provided lateral
158 resolution, we inferred further information about local effects;
159 particularly, we were able to measure and define the time
160 difference between the contraction peak of each pixel within
161 the layer, which we here refer to as the “latency” of the hiPSC-
162 CM contraction. Mechanically, the latency of CMs has rarely
163 been studied due to the lack of spatial resolution.⁴⁹ Electrically,
164 HD-MEA technology allowed the study of ecAP propagation
165 between CMs at cell–cell resolution, which is still missing in
166 the literature²⁸ (Figure 1, Video S2). The quantification of the
167 overall contractility and the latency distribution were efficiently
168 estimated and further validated to differentiate healthy hiPSC-
169 CM with pathology (Brugada syndrome and dilated cardiomy-
170 opathy) and applied to measure the corresponding drug
171 response of diseased hiPSC-CMs (isoproterenol).

172 RESULTS AND DISCUSSION

173 **The *xy*-Inspection Methodology and the Latency.** For
174 a better representation of the tissue function, we considered a
175 layered hiPSC-CMs construct, as it reflects the physiological
176 state of hiPSC-CMs with rhythmic contraction. This
177 configuration also contains abundant connections between

cell layers (cell–cell) and with the substrate (cell–ECM).
These multidimensional cell–cell and cell–ECM interactions
lead to varying contractions at each hiPSC-CM. The intricate
kinetics and synchronization inherent to interacting cells are
challenging to quantify and constitute the primary focus of our
investigation.^{28,50} Mechanically, we combined two methods:
video-microscopy based optical tracker (OPT), and traction
force microscopy (cTFM)⁴⁵ to measure the contractility in
planar force in *x* and *y* of layered hiPSC-CMs.

In the cTFM technique, the strain exerted by the cells
induces a deformation of the elastomer and subsequent
displacement of quantum dots (QDs), which were previously
deposited on the elastomer in the form of hexagonal arrays
(Figure 2 a first panel, Video S1) (for further details, please
refer to the experimental section, cTFM substrate fabrication).
The shape distortion of the QD array from the relaxed state
allows for calculating the active traction being exerted by the
cells onto the substrate with the help of a finite element
method algorithm (FEM).⁵¹ By changing the spacing between
QDs during the printing process, the cTFM lateral sensitivity
can be tuned for single cells and a cell layer. Here, we used
arrays with 5 μm spacing as a good compromise between
lateral resolution and sensitivity, since noise from printing
error increases with smaller spacing. Moreover, since the
elastomer is transparent, concurrent imaging with a confocal
laser scanning microscope (CLSM) was possible. The bright
field (BF) transmitted-light channel was used for the OPT
measurement of the beating hiPSC-CM layer (OPT_BF,
Figure 2b, first panel, Video S1). OPT_BF extracted the
moving features using the Kanade-Lucas-Tomasi (KLT)
algorithm (Figure S2, see details in experimental: OPT_BF
Data Analysis section).^{52–54} Concurrently, the hiPSC-CM
displacement on the elastomer was tracked over time in the BF

(Figure 2b second panel). The displacements were transformed with the Boussinesq equation^{55,56} into μN force. OPT_BF, as it was recently developed, lacks experimental validation, and while cTFM is a well-established TFM method, its application at the tissue level is lacking. Therefore, we validated OPT and cTFM with each other in evaluating the same contraction events of layered hiPSC-CMs.

To ensure faithful quantification of the mechanical contraction of the cells within hiPSC-CM layers, we carefully optimized the mechanical platforms separately. First, cTFM was used to generate a corresponding traction map illustrating the force change over the course of a hiPSC-CMs beat. The traction strain map is a quantitative representation of strain magnitudes within the xy plane in 2D (Figure 2a, second panel) (See details in experimental: cTFM Data Analysis section). These values are typically expressed in kilo-Pascals (kPa)⁵⁷ and can be multiplied by the area of each pixel to obtain information about the local deformation forces. To compare forces between different samples, it is necessary to extract the mean force of a strain map. In order to obtain a mean force that is characteristic of the contractile cells, we need to eliminate inevitable differences in active cell coverage. Therefore, a mask was determined based on the map of hiPSC-CMs at rest and in a contracted state, selecting only the “active” pixels. Superimposing this mask on the traction force map, the contraction was quantified much more precisely, enabling the comparison of force changes over time between different samples (details in Figure S1 and experimental: cTFM Data Analysis section). Second, OPT_BF was tested against variations in brightness, yielding a stable detection of force regardless of the image parameter changes (Figure S2.a,b), eliminating this common problem of video microscopy.^{42,58} By extracting the mean from all of the pixels of the masked strain map in cTFM and plotting it over time, a force profile was generated from cTFM strain maps. Simultaneously, the root-mean-square (RMS) and the mean of the force from all pixels of the moving features (“active pixels”) detected in the OPT_BF force map can also be plotted over time (Figure S2.c). Since the RMS provides a more accurate representation of the overall magnitude of forces, it was chosen to be the comparable average force for each image. The force profiles over time measured by both methods represented the overall beating of the hiPSC-CMs bilayer within the field of view (normally $200 \times 200 \mu\text{m}^2$) (Figures 2c and S1.b,c).

After the initial calibration, we investigated further the temporal dynamics of the hiPSC-CM contraction, taking advantage of the lateral resolution of both methods. Every pixel in the strain/force map exhibited periodic amplitude changes over time, reflecting the rhythmic beating of the hiPSC-CMs. Exemplified with cTFM, these individual force profiles were further analyzed using a peak detection function, generating a distribution of key parameters: peak time points, peak amplitudes, beat duration, and interspike time (Figure S1.d). These parameters are indicators of the sample status and can also be considered measurements of CM contractility in a clinical context from a scalability perspective. For instance, changes in the peak amplitude and interspike time in response to a drug can be indicative of inotropic and chronotropic effects, respectively. Furthermore, the peak time points in each “active pixel” differed (Figure S1.e) (see details in Figure S1 and experimental: cTFM Data Analysis section). Comparing the peak time point of each pixel with the first emergent peak, the relative time difference can be extracted for each pixel

which defines the pixel’s latency. (Figure S1.e). Latency in each “active pixel” can be plotted spatially, displaying the lateral timing difference of the hiPSC-CM contraction (Figure 2a,b third panel). The distribution of all latency values in one image of the contracting hiPSC-CMs can be displayed in a line plot, reflecting the percentage probability of a specific latency value (Figure 2d). This distribution can then be compared between samples and considered as a quantitative representation of the delay in mechanical communication of hiPSC-CMs (Figure 2d).

Following the development of our xy -inspection, we shifted to verify the integrity of the hiPSC-CMs bilayer construct, which is particularly vital when considering the analysis of diseased hiPSC-CMs models.⁵⁹ In the initial stages of our study, we validated the electrical circuit integrity of the CM layer, ensuring that the cell model of our study is functionally correct.⁵⁹ We investigated the electrical activity of hiPSC-CMs with two assays: electrical excitability upon electrical stimulation by xy -inspection and calcium inflow by calcium imaging (see details in Figure S3). Upon electrical stimulation, the hiPSC-CM layer responded practically instantaneously to voltage pulses up to 2 Hz resetting immediately back to spontaneous contraction (Figure S3.a, third panel) upon stopping the pulses. Calcium imaging of the bilayer hiPSC-CMs showed a rapid increase in intensity simultaneously in the whole construct, indicating well-connected cells in the bilayer (Figure S3.c,d). This fast electro-mechanical feedback suggests a complete electrical interconnectivity and functional coupling between the cells.

With the optimized in vitro bilayer model and calibrated xy -inspection, we quantitatively analyzed the contraction of the hiPSC-CM layer, first focusing on the spatial information in the strain/force map. Deformed regions (highlighted colors in Figure 2a,b second panel) were identified on the map. These regions detected from the cTFM measured in the QD channel (Figure 2a second panel) did not spread over the entire image, although the hiPSC-CMs were present in the entire field of view. This indicates that the contraction of hiPSC-CMs detected by the QD is limited on the basal side to areas where the actin-myosin network is connected to the substrate by adhesion. Our observation circles back to the fact that traction in single cells develops mainly at the cell border, corresponding to the adhesion points with the substrate.²¹ OPT_BF displayed a contractile region different from that of cTFM (Figure 2b second panel). The observed difference can be attributed to the different inputs since OPT_BF analyzes the BF channel where hiPSC-CMs are moving in all three directions while cTFM detects x,y contraction in areas where hiPSC-CMs adhere tightly to the elastomer substrate. The higher spread latency values in the OPT_BF measurement are therefore a potential consequence of the more diverse detected cell layer movements in the z -axis compared to the basal contraction, whose traction is limited to the x - and y -axis. The detected disparity in contraction between hiPSC-CMs on the basal side (cTFM) and those observed in BF (features moving in x,y , and z axis) (Figure 2a,b second panel) highlights the complex contraction behavior of hiPSC-CM within a layer.

Although different features were tracked, it can be observed that the mean force profiles of the OPT_BF and cTFM samples were similar (Figure 2c). The spatial differences were more prevalent in the timing of the hiPSC-CM contraction, as indicated by the different latency distribution between the two methods (Figure 2d). Addressing the spatial difference shown




Figure 3. Quantification of mono- and bilayer hiPSC-CMs contraction. (a) Schematic display of the morphological differences in a monolayer (first panel) and a bilayer (second panel) of hiPSC-CM together with examples of immunofluorescent images. (b) Statistical comparison in the amplitude (first panel), beat duration (second panel), and interspike times (third panel) between the two configurations of hiPSC-CMs layer. (c) Corresponding average latency distributions of cTFM (orange: bilayer; darker orange: monolayer) (first row) and OPT (blue: bilayer; darker blue: monolayer) (second row) ($N = 4$ for both mono- and bilayer hiPSC-CMs). The center line represents the mean and the gray zone covers one time the standard deviation from the mean. Mechanical forces in xy (cTFM: orange) and of z (FFM: green) are recorded simultaneously and are overlaid with highlighted peaks (cross in respective color) for monolayer (d) and bilayer (e) configuration. Corresponding time points of these peaks are shown in text right next to them. (f) Immunostaining of the hiPSC-CMs after recording, cyan indicates nuclei and red indicates α -actin positive cells (first panel). Amplitude of ecAP mapped for the whole HD-MEA chip (second panel). (g) Zoom-in ecAP recordings from the HD-MEA were used to derive the electrical characteristics of monolayer (first row) and bilayer (second row) configuration marked with rectangles in (f), their immunostaining images are in the first panel, and their ecAP frequencies are mapped on the recorded electrode (second panel). Corresponding peak time points of ecAP in active electrodes in the second panel are vectorized in the electrical latency map (third panel) with a black star indicating the starting position of ecAP.

337 in the map, we further tested the correlation between the
 338 OPT_BF applied on this data set and cTFM (details in Figure
 339 S4). OPT_BF and cTFM also gave similar values for the
 340 timing (Figure S4.b) as well as the amplitude and beat duration
 341 (Figure S4.d,e). Moving on to quantitative values, we
 342 compared the extracted key parameters (Figure S1.d) across
 343 independent samples ($N = 4$, see experimental: statistical
 344 analysis section). Despite the spatial difference in the
 345 amplitude map, the mean peak amplitudes showed similar

forces between the ± 2 and $\pm 2 \mu\text{N}$ values of OPT_BF (2.6 ± 346
 $0.36 \mu\text{N}$) and cTFM ($2.2 \pm 0.31 \mu\text{N}$), corresponding to 0.065 347
 ± 0.09 and $0.055 \pm 0.08 \text{ mN}/\text{mm}^2$ respectively (Figure 2e). 348
 This force is similar to the forces obtained by Tulloch et al. 349
 using engineered 3D hiPSC-CMs with a mixture of cell types, 350
 having contractility of $0.08 \text{ mN}/\text{mm}^2$.⁶⁰ Averaging latency 351
 across samples ($N = 4$, see experimental: statistical analysis 352
 section sec4.9), cTFM and OPT_BF converged at the same 353
 latency mean (cTFM: $0.10 \text{ s} \pm 0.008$, and OPT_BF: 0.10 ± 354

355 0.022 s). However, OPT_BF has a broader latency distribution
356 with a higher full width at half-maximum (cTFM: 0.10 ± 0.049
357 s; OPT_BF: 0.20 ± 0.062 s). (Figure 2f) This suggests a
358 temporal disparity in contraction between hiPSC-CMs on the
359 basal side and the features across the z -axis observed in BF.
360 Combined with the spatial disparity described above, we
361 hypothesize that OPT_BF detects (1) feature displacement on
362 the top layer independently from (2) basal adhesion.

363 **Contraction of hiPSC-CM Mono- and Bilayers.** We
364 have demonstrated that our xy -inspection is capable of
365 resolving not only the hiPSC-CM contractility but also the
366 mechanical cell–cell coupling through latency analysis.
367 Intuitively, the latency is intricately associated with the number
368 of cell junctions and the cell-ECM interactions. The fact that
369 hiPSC-CM is organized in layers mimics the physiological state
370 with rhythmic contraction and abundant cell–cell connections.
371 To further extend the latency analysis toward quantifying cell–
372 cell interactions, we compared the hiPSC-CM bilayer with a
373 single layer of hiPSC-CMs obtained using reduced seeding
374 densities (confluent monolayer: 1000 cells/mm² and confluent
375 bilayer: 2000 cells/mm²) (Figure 3a).

376 Structurally, the hiPSC-CM monolayer exhibited slight
377 nuclei enlargement ($162.86 \pm 50.53 \mu\text{m}^2$), with approximately
378 30 cells occupying an area of 0.04 mm² (Figure 3 in the first
379 panel). Conversely, in the bilayer configuration, hiPSC-CMs
380 displayed smaller nuclei ($146.35 \pm 51.40 \mu\text{m}^2$) and a
381 distinctive bilayer structure was observed through a different
382 nuclei location pattern at different z focus in the z stack
383 imaging (Figure 3a second panel, Figure S3.e,f). This
384 manifested as thicker layers with varying levels of homogeneity
385 (Figure 3a second panel side view; Figure S3.e,f). In this
386 configuration, there were approximately 80 cells within the
387 same 0.04 mm² area. Contractility quantification of these two
388 configurations revealed a higher peak amplitude of the hiPSC-
389 CM bilayer ($\approx 2.5 \mu\text{N}$) than the monolayer ($\approx 1 \mu\text{N}$) with a
390 comparable beat duration and frequency (Figure 3b). Apart
391 from the contractility difference, interestingly, a prominent
392 peak around 0.15 s in the latency of the OPT_BF was evident
393 in the monolayer hiPSC-CMs, compared to a flat latency
394 distribution across different values in the bilayer configuration
395 (Figure 3c second row). These two configurations likely
396 involve different timings for contraction, further emphasizing
397 the complexity of evaluating the collective contraction of
398 hiPSC-CMs. Statistically, the monolayer of hiPSC-CMs
399 showed a less delayed mean latency of 0.07 ± 0.011 s and a
400 broader fwhm of 0.133 s, compared to the 0.10 ± 0.008 s
401 average latency and 0.1 s fwhm obtained by cTFM for the
402 bilayer (Figure 3c, first row). We found a similar trend in the
403 OPT_BF measurements (latency mean of bilayer; fwhm of
404 averaged distribution: 0.10 ± 0.022 s; 0.2 s, monolayer: $0.11 \pm$
405 0.010 s; 0.033 s) (Figure 3c second row). The broader
406 distribution in the bilayer hiPSC-CM could be due to more
407 diverse moving features in the bilayer hiPSC-CM, including
408 both hiPSC-CMs adhering tightly to the substrate and hiPSC-
409 CMs connecting to each other. Therefore, we could describe
410 the bilayer contraction as more “free-standing” in comparison
411 with the monolayer.

412 To further investigate the differences between the mono-
413 and bilayer configurations, we conducted a 3D force recording
414 (xyz -inspection).⁶¹ This 3D contractility measurement pro-
415 vided additional information along the z -axis, probing on the
416 apical side of the hiPSC-CM layer. Mechanical forces were
417 concurrently recorded in both the xy -plane (using cTFM) and

the z direction (utilizing FFM) (Figures 3d,e and S5; see 418
419 details in experimental: xyz -Inspection section). The vertical
420 contractility of a hiPSC-CM layer differed spatially in
421 amplitude (Figure S5.b–d),⁶² yet preserved the same force
422 profile characteristics such as duration and frequency (Figures
423 3e, and S5.d). This combined measurement, including the
424 force recorded from FFM at the apical side and from cTFM at
425 the basal side, highlighted the 3D latency. Fixing the cTFM as
426 the reference measurement for the basal side of the hiPSC-CM
427 layer at time $t = 0$, it appeared that the contractions recorded
428 from FFM occurred earlier in time. Furthermore, the FFM
429 vertical delay (vs cTFM) was larger in the bilayer morphology
430 (0.075 ± 0.014 s), compared to the monolayer (0.050 ± 0.019
431 s) (Figure 3d,e). This could further confirm the “free-standing”
432 feature of the bilayer configuration, as it contracts with more
433 delay in the z -axis.

As electrical signals mark the start of a hiPSC-CM 434
435 contraction, electrophysiology measurements could investigate
436 further the latency difference between the two configura-
437 tions.⁶³ We employed high-density multielectrode arrays (HD-
438 MEA, see experimental: HD-MEA Data Analysis section for
439 further details) to record the extracellular action potential
440 (ecAP) of hiPSC-CMs adherent to the sensor area. The ecAP
441 derived from this methodology was previously validated as a
442 practical indication of the model assay for drug development.⁶⁴
443 Unlike traditional MEA measurements, where recordings
444 include collective ecAP from multiple cells on the same
445 electrode, the HD-MEA measured both the amplitude and the
446 frequency of ecAPs with high temporal and lateral resolution
447 (0.05 ms; 17.5 μm electrode pitch), sufficient to resolve single
448 cell electrical activity and cell–cell electrical communica-
449 tion.^{33,34,65} However, HD-MEA sensors are rigid which may
450 stress hiPSC-CMs due to the stiff ECM.⁶⁶ This unmatched
451 ECM stiffness in the electrical recording (HD-MEA: GPa)
452 with that of the mechanical measurements (xy - and xyz -
453 inspection: 13.7 kPa⁶⁷) affects the hiPSC-CM contraction
454 characteristic by cell-ECM interaction. Therefore, targeted
455 HD-MEA experiments were performed only to provide
456 additional information with a limited number of independent
457 samples (see details in the experimental HD-MEA Data
458 Analysis section).

Focusing on the cell–cell communication, the lateral 459
460 morphological characteristics were verified by postexperiment
461 immunofluorescent staining on formaldehyde-fixed samples
462 (Figure 3f first panel), since the HD-MEA are not transparent
463 for microscopy techniques. The amplitude and frequency map
464 of the ecAP corresponded well to the cell coverage (Figure 3f,
465 second panel), matching the fluorescent image (Figure 3f, first
466 panel). In order to measure in detail the electrical activity at
467 the cell–cell interface, zoom-in recordings of the hiPSC-CM
468 were conducted on HD-MEA chips as the maximum number
469 of parallel recording electrodes on the HD-MEA is 1024
470 (Figure 3g, h). When selecting the recording electrodes, it was
471 possible to identify if the selected cells are in a monolayer or a
472 bilayer configuration comparable to what was defined in the
473 mechanical measurements of the hiPSC-CMs, based on the
474 ecAP activity in the frequency maps and the fluorescent images
475 (Figure 3g,h).

Additionally, corresponding examples of ecAP profiles were 476
477 averaged for each contraction in these zoom-in recording in
478 Figure S6.a,b. Similarly to the mechanical map, the difference
479 in ecAP peak time points can be extrapolated onto the
480 electrical latency map (zoom-in: Figure 3g,h third panel, whole

481 chip: Figure S6.c; see details in the Experimental: HD-MEA
482 Data Analysis section). The first emergence of ecAP in all
483 recorded electrodes can be determined due to the high
484 temporal resolution of the MEA system (0.05 ms). Therefore,
485 we mapped the electrical latency with arrows indicating the
486 direction of ecAP propagation based on the latency of ecAP
487 peak timing (Figure 3g,h third panel). Such signal propagation
488 repeated periodically along with the rhythmic contraction of
489 the CMs; therefore, we further extracted the electrical latency
490 distribution to quantify the electrical propagation of the
491 hiPSC-CMs (Figure S6.d,e). The electrical latency map
492 combined with its distribution in a whole chip (most active
493 1024 electrodes selected) revealed that the ecAP propagated
494 from the left of the chip to the right within 5 ms (Figure S6.c,d,
495 Video S2). Comparing zoom-in recordings of hiPSC-CM in
496 different configurations, the hiPSC-CM monolayer presented a
497 dominant 1.2 ms peak in electrical latency, accompanied by
498 another two peaks at around 2.7 and 4.2 ms (Figure S6.e).
499 These two secondary electrical latency peaks could be due to
500 the hiPSC-CMs at the corresponding positions not being
501 electrically connected to the main hiPSC-CMs electrical event
502 (1.2 ms), as suggested by the latency map.

503 In contrast, the hiPSC-CMs in a bilayer configuration in
504 which the cells cover the entire field of recording had two main
505 electrical latency peaks at 1.3 and 1.7 ms (Figure S6.e), without
506 other latency peaks at higher values. Although we did not
507 observe a broader latency distribution electrically in the bilayer
508 configuration as in the mechanical measurement, the ecAP
509 propagation differed between monolayer and bilayers, showing
510 a reduction of electrical connection in the monolayer
511 configuration.

512 The mechanical map of the hiPSC-CM contraction is rich in
513 lateral resolution, providing $0.4 \mu\text{m}/\text{pixel}$ (xy -inspection, xyz -
514 inspection: $0.1 \mu\text{m}/\text{pixel}$) resolution, showing hundreds of ms
515 mechanical latency difference between layers of hiPSC-CMs.
516 Although the temporal resolution of the mechanical
517 quantification is limited by the inherent acquisition rate of
518 the camera mounted on the microscope (xy -inspection: 0.033
519 s/frame and xyz -inspection: 0.025 s/frame; field of view: ≈ 0.04
520 mm^2), the latency results reported here lay within the range
521 with respect to the long mechanical beat duration (1.2 s) (36
522 and 48 frames within one contraction for xy -inspection and
523 xyz -inspection, respectively).

524 The electrical communication of hiPSC-CMs with relatively
525 short ecAPs (duration: 200 ms)⁶⁸ can only be resolved with
526 techniques with both high temporal and lateral resolution such
527 as the HD-MEA that is used in this work (Figure 3f–h).
528 Compared to patch clamp, which only allows parallel
529 measurements of a limited number of cells, HD-MEA, which
530 records 1024 pixels with a spatial resolution of $17.5 \mu\text{m}$ per
531 pixel, provides an improved advantage in resolving cell–cell
532 communication. Moreover, compared with the mechanical
533 latency map, we could derive the electrical propagation path
534 across the cell–cell interface thanks to the high temporal
535 resolution (4000 frames, $50 \mu\text{s}$ per frame, within one
536 contraction). Therefore, ecAP recording has the suitable
537 spatiotemporal resolution for the hiPSC-CMs electrical
538 communication, described as electrical latency in this work.

539 Upon comparison of the mechanical and electrical latency,
540 an order of difference in latency values in the mechanical
541 (hundreds of milliseconds) and electrical measurements (ms)
542 was observed. There is indeed an expected time difference
543 between the peak of ecAP and mechanical contraction,⁶⁹ which

should be in the range of tens of ms due to the cardiac
excitation-contraction coupling.⁵ However, since each cell
(from the one that starts contraction to the one that contracts
last) is expected to have about the same inherent time
difference, the overall mechanical latency should be the same
as the electrical latency. Therefore, the long mechanical latency
that we observed here suggests an electromechanical delay as
previously demonstrated⁷⁰ in a paced hiPSC-CM layer on a
rigid substrate, measuring around 100 ms delay of a layer of
hiPSC-CMs. We further hypothesized that this delay is also a
result of mechanical inertia within the coordinated hiPSC-CM
layer, which does not exist in a single hiPSC-CM. Starting from
a local action potential, the corresponding hiPSC-CMs initiate
their mechanical contraction, which simultaneously exerts
pulling on the neighboring hiPSC-CMs. This process repeats
in a chain of reactions within a network of hiPSC-CM until the
hiPSC-CM layer completes a coordinated beat, which is
registered either with cTFM through focal adhesion sites or
with OPT_BF through the feature movement. From the macro
perspective, the elasticity and local mass of the layer delay the
force development in muscle tissue⁷¹ and correlate with the
mechanical inertia. The ecAP measured in this work with even
shorter electrical characteristics can only enhance this
difference in latency. In this work, the degree of mechanical
inertia depends on the complexity of interactions such as
excitation-contraction coupling within each cell, cell–cell
connections, and cell-ECM interactions. Compared to a
previous electromechanical wave study by Liu et al. (30
 μm),⁷⁰ we presented a higher lateral resolution with
contractility quantification, resolving the mechanical coupling
of hiPSC-CM with each other, which is especially complicated
in the hiPSC-CM layer.

The broad latency distribution of hiPSC-CM contraction
observed from both mechanical and electrical measurements
could arise from the inherent limitations of hiPSC-CMs in
establishing connections with each other.⁷² The mechanical
inertia in hiPSC-CMs can be explored more thoroughly via an
in vitro model that includes supporting cells, such as cardiac
fibroblasts which could modulate the mechanical coupling by
producing ECM.⁷² The physical linkage between the ECM and
the cytoskeleton, established by the focal adhesions, controls
the complex bidirectional mechanical forces. Previous studies
have shown that substrate stiffness influences the expression of
the connexin isoform 43 and the calcium handling of hiPSC-
CMs⁴⁹ as well as their contractility.⁷³ CMs on stiffer substrates
have a larger contractility in xy ⁷³ and a smaller force in z ⁴⁹
compared to CMs on soft substrates, suggesting that when
contracting, CMs deform easier in 3D when adherent on softer
substrates.⁷⁴ In the bilayer configuration, the top layer binds to
the bottom hiPSC-CMs which has a Young's modulus of 1.25
kPa,⁷⁵ while the bottom layer adheres to the cTFM substrate
or the HD-MEA, which has a modulus of 13.7 kPa or tens of
GPa, respectively. From the mechanotransduction perspective,
it is not surprising to observe the different mechanical and
electrical propagation patterns between the bilayer and the
monolayer of hiPSC-CMs. Moreover, mechanical conduction
is faster with CMs adherent to a softer substrate.⁴⁹ This
matches the observations of mechanical latency differences
found between the hiPSC-CM bilayer and monolayer with xy -
inspections, where more diverse latency values were present in
the hiPSC-CM bilayer configuration. Therefore, we attribute
the larger mechanical inertia, indicated by the decreased mean
latency detected by cTFM and the broader latency distribution




Figure 4. Quantification of diseased hiPSC-CMs contraction. (a) Immunofluorescent staining of CTRL, BRU, DCM, and isogenic DCM diseased cell lines in a bilayer configuration. (b) Contractility quantification of hiPSC-CMs analyzed by xy-inspection providing statistical comparison in amplitude (first panel), beat duration (second panel) and interspike time (third panel) ($N = 4$ for all conditions, n.s. stands for not significant, * $p < 0.05$, ** $p < 0.001$, *** $p < 0.0001$, **** $p < 0.00001$, ***** $p < 0.000001$). (c) Latency distributions of CTRL, BRU, DCM, and ISOGEN analyzed by cTFM (first panel) and by OPT_BF (second panel). Xyz-inspections on CTRL (d), BRU (e), and DCM (f), providing 3D force profiles with peak time points indicated next to the peaks.

607 seen in OPT_BF (Figure 3c), to the “free-standing” character-
 608 istics of the hiPSC-CMs bilayer. Furthermore, more feature
 609 movements covering the hiPSC-CM contraction in the vertical
 610 axis in the bilayer configuration were measured by a larger 3D
 611 latency delay than the monolayer configuration with xyz-
 612 inspection. A further detailed investigation into the coupled
 613 cell-ECM and cell–cell interactions could include a soft ECM
 614 surrounding CMs, such as a hydrogel-based cell encapsulation
 615 system while recording the local contraction with high lateral
 616 resolution.

617 **Contraction of Diseased hiPSC-CMs.** The coordination
 618 of the hiPSC-CMs in a layer does not only rely on the
 619 cooperative coupling of the cell-ECM and cell–cell inter-
 620 actions but is also tightly correlated to the functional
 621 contraction of every single hiPSC-CM, all of which can be
 622 altered by diseases and pathological conditions. After
 623 characterizing the contraction of hiPSC-CMs from healthy

624 donors both electrically and mechanically (CTRL), we
 625 extended the study with two different diseased hiPSC-CM
 626 cell lines (Brugada syndrome and Dilated Cardiomyopathy)
 627 to assess whether these diseases modify any of the previously
 628 described quantitative parameters (Figure 4).^{7,10}

629 Brugada syndrome is a hereditary ion channel disorder that
 630 increases the risk of ventricular arrhythmias and sudden cardiac
 631 death. Here, we used engineered hiPSC-CMs with artificially
 632 introduced Cav1.2 (CACNA1C: loss-of-function) gene
 633 (G490R specifically) into a donor with no known disease-
 634 related genotypes (BRU) (Figure 4 is a second panel). Cav1.2,
 635 a voltage-gated L-type calcium channel, serves as a crucial
 636 mediator of the cardiac action potential.⁷⁶ Given its function as
 637 the primary channel regulating calcium entry for excitation-
 638 contraction coupling, the loss of function in this channel leads
 639 to bradycardia and arrhythmias.⁷⁶ Dilated cardiomyopathy
 640 (DCM) is typically diagnosed clinically by ventricular dilation




Figure 5. Response of hiPSC-CMs to isoproterenol. Contraction quantification and latency distributions with (a, b) cTFM and with (c, d) OPT_BF of spontaneously beating and isoproterenol stimulated hiPSC-CMs in CTRL, BRU, and DCM conditions. CTRL ($N = 4$), BRU ($N = 4$), and DCM ($N = 4$) (* $p < 0.05$, ** $p < 0.001$, *** $p < 0.0001$, **** $p < 0.00001$, ***** $p < 0.000001$. Not labeled statistics are not significantly different.

641 and reduced heart contractility, representing a disease in which
 642 mechanobiology plays an important role.¹⁰ In our study, we
 643 focused on hiPSC-CMs derived from an individual with DCM
 644 pathology, specifically a donor carrying lamin A/C (LMNA:
 645 L35P) protein mutation¹⁰ (DCM) (Figure 4a third panel). To
 646 expand the application of our methodology in the genetic
 647 etiology of DCM, we introduced the engineered isogenic
 648 control of DCM with L35P correction, as stated by the
 649 producer (ISOGEN) (Figure 4a fourth panel).

650 We have quantitatively assessed the behavior of both mono-
 651 and bilayers of the diseased hiPSC-CMs by using the
 652 methodology described above. Monolayers hiPSC-CMs mainly
 653 differed in interspike time (Figure S7.c), especially between
 654 CTRL and BRU. Bilayers hiPSC-CMs seemed to have a more
 655 pronounced difference in the measured overall mechanical
 656 quantitative parameters (Figure 4). Consequently, we chose to
 657 focus on the hiPSC-CM bilayer condition for both healthy and
 658 diseased cell lines, as it is also more relevant for the study of
 659 cell–cell interactions.³ Statistical results revealed that both
 660 BRU and DCM have a reduced beating amplitude, with both
 661 cTFM and OPT_BF being in agreement (Figure 4b). DCM

had a longer beat duration and interspike time (lower beating
 662 frequency) than BRU and CTRL and sometimes showed
 663 arrhythmia detection which indicates a more severe mechanical
 664 pathological condition, matching the reduced contractility of
 665 DCM samples (Figure 4b). The ISOGEN displayed an
 666 increased trend in amplitude compared to DCM hiPSC-
 667 CMs, however still had a longer beat duration and higher
 668 interspike time compared to the healthy hiPSC-CMs (Figure
 669 4b). Such observation indicates that the DCM pathology
 670 involves additional genetic mutations other than the L35P,
 671 resulting in a reduced contraction.⁵⁸ The comparison of the
 672 isogenic control of DCM alleviates the differences in the
 673 genetic background of the donor of hiPSC-CMs, focusing the
 674 quantification on the specific genetic mutation. This further
 675 highlights the significance of hiPSC-CMs in the study.
 676

After a statistical analysis of the diseased hiPSC-CMs, we
 677 focused on latency comparison. cTFM measured increasingly
 678 higher fwhm of latency distributions for BRU (0.17 s) and
 679 DCM (0.20) compared to CTRL (0.10 s). The mean latency
 680 of DCM and BRU measured from cTFM shifted toward higher
 681 values (BRU and DCM averaged at 0.16 ± 0.016 and $0.20 \pm$
 682

683 0.029 s respectively vs CTRL at 0.11 ± 0.010 s) (Figure 4c first
684 panel).

685 OPT_BF analysis had less obvious trends in latency
686 distribution but also displayed a greater percentage of higher
687 latency values measured in BRU and DCM (Figure 4c second
688 panel). The delay in latency means detected by OPT_BF
689 became more severe with DCM, having an average of $0.21 \pm$
690 0.033 s (CTRL: 0.10 ± 0.022 s). This difference was less
691 pronounced in BRU samples measured by OPT_BF, with an
692 average latency of 0.16 ± 0.024 s (Figure 4c, second panel).

693 The xyz-inspections of the diseased hiPSC-CMs revealed
694 distinct characteristics compared to healthy hiPSC-CMs
695 (Figure 4c–e). In BRU samples, a notable double-peak feature
696 and an FFM latency of 0.325 ± 0.224 s compared with the
697 cTFM measurement in the contraction was observed (Figure
698 4d). Likewise, in DCM, a large 3D latency difference was seen,
699 with -0.225 ± 0.122 s in the FFM anticipated to the cTFM
700 (Figure 4e). These 3D latency features of BRU and DCM
701 suggested irregularities in mechanical conduction along the z-
702 axis in diseased hiPSC-CMs.

703 Apart from the measured contractility reduction, also a
704 noticeable delay in mechanical latency was observed in the
705 diseased hiPSC-CM layer, suggesting a larger mechanical
706 inertia. This could stem from the defective coupling between
707 hiPSC-CM within the layer. Specifically, DCM hiPSC-CMs
708 have the LMNA defect, which results in reduced force
709 transmission from the sarcomere to the ECM, leading to the
710 broadest latency distribution. At the same time, the defective
711 mechanical coupling in BRU is interesting as the Cav1.2 defect
712 is not typically associated with mechanical disorders. The fact
713 that an ion channel defect results in larger mechanical inertia
714 indicates the important role of excitation-contraction in the
715 mechanical coupling of hiPSC-CMs.

716 The characterization of the electrical activity of diseased cell
717 lines is equally essential in identifying pathological condi-
718 tions.^{8,13} The loss-of-function Cav1.2 in BRU samples
719 generates a shortened action potential duration and short
720 QT intervals with a reduced calcium current.⁷ Therefore, we
721 expected to find the observed differences in the electro-
722 physiological behavior of the BRU hiPSC-CMs. Similarly,
723 although DCM primarily affects the heart structure mainly by
724 ventricular dilation, it also leads to electrical abnormalities as a
725 secondary consequence.⁸ Despite the rigidity mismatch
726 between mechanical and electrical measurements, HD-MEA
727 was needed for electrical characteristic registration of diseased
728 hiPSC-CMs (details in Figure S8). The latency analysis
729 showed that ecAP propagation in BRU has a higher delay
730 compared to that in the healthy hiPSC-CMs (Figure S8). This
731 electrical delay may be attributed to the loss of function in
732 calcium channels, leading to an overall reduced Ca²⁺ trafficking
733 in each hiPSC-CM and also between hiPSC-CMs. DCM
734 hiPSC-CMs by definition are “mechanically defective”⁹ and
735 our analysis demonstrated a milder delay with a latency; the
736 correction of the LMNA mutation (Isogenic DCM) leads to a
737 recovery of the electrical propagation (see details in Figure
738 S8). The limitation of this study is the separate recording of
739 the electrical and mechanical activity, performed on different
740 platforms with drastically different rigidity. An envisioned
741 improvement would be the simultaneous mapping of the
742 electrical and mechanical activities to further investigate the
743 effect of cell–cell and cell–ECM coupling by using, e.g.
744 different seeding densities and tunable substrate Young’s
745 modulus.

Response of hiPSC-CM Bilayers to Isoproterenol. 746

747 Finally, we investigated how the in vitro models (CTRL, BRU,
748 and DCM samples) respond to isoproterenol to assess the
749 suitability of our platform for investigating drug-induced
750 effects. We treated the hiPSC-CMs with isoproterenol (1
751 μ M), which is known to upregulate the cardiac β -adrenergic
752 pathway with an expected increase of contractility, beating
753 frequency (positive inotropic and chronotropic effects), and
754 conduction velocity.^{77–79} Overall, we did not measure any
755 positive inotropic effect of isoproterenol (Figure 5a first panel),
756 which can be an indication of the immaturity of the hiPSC-
757 CMs, as reported in the literature.^{22,80,81} A positive
758 chronotropic effect was confirmed in both cTFM and
759 OPT_BF by the two-fold decrease in the interspike time and
760 a halving of the beating duration compared to the untreated
761 hiPSC-CMs (Figure 5a,b).

762 Focusing on the response of the diseased hiPSC-CMs
763 toward isoproterenol, BRU hiPSC-CM samples were majorly
764 rescued with shortened beat duration and a smaller interspike
765 time, while DCM hiPSC-CMs still presented significantly
766 longer beats and interspike time compared to the untreated
767 CTRL (Figure 5a,b). We found no significant differences in
768 average latency between spontaneous (cTFM: 0.1 ± 0.008 s;
769 OPT_BF: 0.10 ± 0.022) and isoproterenol treated (cTFM:
770 0.09 ± 0.006 s; OPT_BF: 0.10 ± 0.016) contraction of CTRL.
771 Similarly for BRU, which showed an average latency at $0.18 \pm$
772 0.025 s (OPT_BF: 0.12 ± 0.022 s) with isoproterenol (Figure
773 5c,d, second panel) compared to 0.16 ± 0.016 s (OPT_BF:
774 0.15 ± 0.024 s) for spontaneous contraction. In contrast, we
775 observed a larger latency mean change in DCM compared to
776 BRU, exhibiting a smaller mean latency centered at $0.16 \pm$
777 0.013 s (OPT_BF: 0.16 ± 0.05 s) compared to spontaneous
778 beating (0.21 ± 0.03 s, OPT_BF: 0.21 ± 0.033 s) (Figure 5c,d,
779 third panel). Importantly, a clear narrower latency distribution
780 in all cell types is measured by cTFM with the fwhm of the
781 mean distribution compared in spontaneous and isoproterenol-
782 treated contraction (CTRL: 0.10; 0.03 s; BRU: 0.17; 0.07 s;
783 DCM: 0.20; 0.10 s) (Figure 5d first panel). The same trend is
784 also observed in the OPT_BF analysis (CTRL: 0.20; 0.13 s,
785 BRU: 0.07; 0.03 s, DCM: 0.23; 0.07 s; Figure 5d, second
786 panel).

787 To summarize, the latency analysis measures a partial
788 mechanical coupling recovery by isoproterenol, which
789 demonstrates the sensitivity of the mechanical measurements,
790 making it also applicable in drug assessment. The decreased
791 mean latency in DCM samples with isoproterenol confirms
792 what in the literature has been assessed as the role played by
793 impaired Ca²⁺ trafficking, a key dysfunction contributing to
794 arrhythmogenesis in this cardiomyopathy.⁸² The unchanged
795 mean latency in BRU indicates that the enhanced calcium
796 trafficking from the β -adrenergic receptor activation could not
797 fully compensate for the defective excitation-contraction
798 coupling caused by the loss of function in the calcium
799 voltage-sensitive channel mutation.^{83,84}

800 The β -adrenergic upregulation observed in the mechanical
801 activity can also be observed in the parallel electrical
802 measurements (details in Figure S9), with targeted experi-
803 ments on CTRL and BRU, again considering the effect of rigid
804 HD-MEA on cell–ECM interactions. We compared the ecAPs
805 of hiPSC-CMs within the same zoom-in field of view under
806 spontaneous contraction and after isoproterenol stimulation
807 (Figure S9). In healthy hiPSC-CMs, the spontaneous
808 frequency of ecAP doubled (0.5 Hz vs 1 Hz under

809 isoproterenol treatment), and the latency distribution shifted
810 toward lower values with a peak at 0.78 ms, in contrast to
811 spontaneous activity (1.64 ms) (Figure S9.a–c). The BRU
812 response to isoproterenol was electrically present, not only in
813 the chronotropic effect but also in the altered latency
814 distribution (Figure S9.d–f). In the electrical latency map,
815 we observed a different conductive pathway in the isoproter-
816 enol-stimulated BRU, where the ecAP propagates faster from
817 the lower right to the middle until the upper regions of the
818 field of view (Figure S9). This also aligns with the accelerated
819 conduction velocity by β -adrenergic modulation from iso-
820 proterenol.^{77,79}

821 CONCLUSIONS

822 In this work, cTFM and OPT_{BF} served as mutual validation
823 in quantifying the hiPSC-CM contractility and together
824 demonstrated great potential in measuring the cell–cell
825 mechanical coupling. Specifically, the introduced xy-inspection
826 and xyz-inspection complemented the traditional contraction
827 analysis with latency quantification. Furthermore, the electrical
828 latency was characterized by targeted ecAP mapping with HD-
829 MEA, resolving the electrical propagation pathway within the
830 hiPSC-CM layers. We provided a complete set of latency
831 evaluations, being able to distinguish between mono- and
832 bilayer hiPSC-CM configurations and between healthy and
833 diseased hiPSC-CM layers. Combined with contraction
834 measured with FFM at the z-axis, a more spread latency in a
835 bilayer hiPSC-CM configuration was shown in both 2D and
836 3D, highlighting the larger mechanical inertia in the bilayer
837 configuration. In diseased hiPSC-CM layers, a noticeable delay
838 in both mechanical and electrical latency was observed,
839 indicating defective coupling between hiPSC-CM within the
840 layer. This defected coupling could be partially rescued with
841 the activation of the β -adrenergic pathway, validating the
842 applicability of the proposed technique for drug assessment. In
843 conclusion, the mechanical and electrical analyses proposed in
844 this work provided different insights into the signal conduction
845 of cardiac in vitro models. Notwithstanding that the hiPSC-
846 CM mono- and bilayers do not have the grade of biological
847 complexity to be rationalized as multilayers or 3D models, they
848 ensure a high sensitivity enough to reliably detect pathological
849 conditions for possible applications in pharmaceutical research.

850 EXPERIMENTAL SECTION

851 **Fabrication of cTFM Substrates.** Glass coverslips were first spin-
852 coated with CY52–276 silicone (DOWSIL, USA) using a 9:10 mixing
853 ratio with components A and B, resulting in an elastic modulus of
854 approximately 13.7 kPa.^{45,61} Details of the silicone preparation can be
855 found in the study of Reyes Lua et al.⁶⁷ Subsequently, red-emitting
856 quantum dots (CdSe, QD) in the form of nanodiscs were precisely
857 deposited onto these silicone substrates in hexagonal arrays (210 ×
858 210 μm^2 each), maintaining a spacing of 5 μm between discs. This
859 deposition was achieved using the electrohydrodynamic nanodrip
860 printing technique, as previously reported by Bergert et al.⁴⁵ For the
861 experiments, the prepared substrates were fixed to bottomless Petri
862 dishes (WillCo Wells, NL) for cell culture with double-sided adhesive
863 provided by the Petri dish manufacturer.

864 **Cell Culture.** hiPSC-CMs were purchased from Fujifilm Cellular
865 Dynamics Solutions (USA). The CTRL hiPSC-CM was derived from
866 a healthy donor clone 11,713. BRU hiPSC-CM was an artificial cell
867 line that engineered the Cav1.2 loss-of-function gene in a healthy
868 donor with clone number 01434. DCM hiPSC-CM was derived from
869 individual mice (clone 01016) with dilated cardiomyopathy. Isogenic
870 control of DCM hiPSC-CM was corrected with the L35P genetic
871 missense of the DCM hiPSC-CM cell line. xy-inspection and xyz-

inspection use the cTFM substrate prepared with the same methods
described above. The cTFM substrates were coated with vitronectin
(Sigma, USA) (50 $\mu\text{g}/\text{mL}$ in DPBS (Thermo Fisher, USA)) for 2 h at
37 °C before cell seeding, and finally washed with DPBS twice before
cell seeding.

Cells were thawed and handled according to the manufacturer's
recommendations, in terms of the warm-up procedure and usage of
specific medium. Two seeding densities were used to obtain either
monolayers (1000 cells/ mm^2) or bilayers of cells (2000 cells/ mm^2).

The HD-MEAs (Maxwell Biosystems, Switzerland) were prepared
with the same coating protocol as the cTFM substrate described
before; 100,000 cells were seeded on each HD-MEA. Two days after
plating, the plating medium was replaced with a maintenance medium
supplied by Fujifilm to guarantee cell viability and functionality. Cells
were incubated at 37 °C and 5% CO₂ for at least 10 days to allow for
proper cell attachment to the substrate. The maintenance medium
was refreshed every 2 days during the whole experiment according to
the manufacturer's instructions.

xy-Inspection. Both BF and fluorescent (cTFM: QD) images
were acquired by a confocal laser scanning microscope (CLSM)
(Olympus Fluoview FV3000) with temperature and CO₂ control. A
488 nm argon laser was band-passed before illuminating the sample
and exciting red QDs with an emission window of 550 to 650 nm.
One minute acquisition on each sample were acquired with a 60×
objective, having a numerical aperture of 1.35, at 30 frames/s.

xyz-Inspection. We selected FluidFM commercial tipless silicon
nitride probes (Cytosurge AG, Switzerland) with a 2 μm circular
aperture and low spring constants (initially 0.2 N/m). According to
the thermal tuning calibration,^{85–88} these probes have an average
spring constant of 0.26 N/m. The deflection sensitivity was calibrated
by averaging the slopes of deflection versus voltage from four forward
force spectra recorded on glass in PBS (Thermo Fisher, USA) before
each experiment. A 4 μm bead (Degradex, USA) was attached to the
cantilever with negative pressure. The experiments were conducted at
37 °C within an incubation chamber (Life Imaging Services, 906
Switzerland). The cTFM samples with a hiPSC-CM layer were
mounted on a live-cell, wide-field fluorescent microscope (Axio
observer, Zeiss, Germany) equipped with the FluidFM system
(FlexAFM-near-infrared scan head with a C3000 controller driven
by the EasyScan2 software, Nanosurf AG, Switzerland). The highest
point within the hiPSC-CM layer was selected for probing based on a
z-stack of images. For each experiment, we selected 2–3 highest
points to measure the z force. The approach set-point for force
detection was set at 10 nN to ensure a gentle yet effective contact
between the cantilever and the hiPSC-CM layer. The imaging of
cTFM in the red channel was performed with a CMOS ORCA-flash
camera (Hamamatsu, Japan) using a 63× objective, having a
numerical aperture of 1.34 at 40 frames/s. The simultaneous
recording of imaging information (shutter opening), deflection, and
piezo movement was integrated into a DAQmx device (BNC-2090A,
National Instruments, US). The force recorded with FluidFM and
cTFM can then be synchronized based on the shutter opening,
assigning the correct z force to the xy force in time.

Immunostaining. Samples were fixed with 4% formaldehyde
solution (Sigma-Aldrich, USA) for 10 min at room temperature. After
fixation, the samples were washed three times for 5 min with 1×
Phosphate buffer solution (PBS, Gibco, USA). Permeabilization of the
cell membranes was performed with a 10 min incubation step in
Dulbecco's phosphate buffered solution (DPBS, Gibco, USA) 930
supplemented with 1% bovine serum albumin (Sigma-Aldrich, 931
USA) and 0.1% Triton-X100 (Sigma-Aldrich, USA). After washing 932
thoroughly with 1× DPBS, the samples were incubated with primary 933
antibody (Mouse Antisarcomer Alpha-actin, Abcam, MS-295, UK) 934
resuspended with a dilution factor of 1:200 in blocking buffer (DPBS 935
with 0.1% goat serum), overnight at 4 °C. On the following day, after 936
washing steps, incubation with the secondary antibody solution 937
diluted in the blocking buffer (Alexa Fluor 488 goat antimouse, 938
concentration 1:100, Thermo Fisher Scientific, A28175, USA) was 939
performed for 2 h at room temperature. Lastly, after the unbound 940
antibody was washed off, the samples were incubated with Hoechst

942 33342 solution (Thermo Scientific, 62249, USA). Finally, the cells
943 were imaged within 2 days to prevent any bleaching of the
944 immunofluorescent signal.

945 **cTFM Data Analysis.** To calculate the traction forces during
946 hiPSC-CM beating, we employed image analysis using the previously
947 developed software, Cellogram,⁵¹ which does not require a reference
948 image. Instead, it relies on establishing the theoretical initial position
949 of the ordered QD nanodisc array and comparing it with the
950 experimentally acquired images to determine the QD displacement
951 field $\Delta\mathbf{u}$. Subsequently, using the known material properties of the
952 substrate, the traction force vector field \mathbf{F} was computed with a linear
953 elastic material model⁵¹:

$$954 \quad \mathbf{F} = \frac{E}{2(1+\nu)}\Delta\mathbf{u} + \frac{E}{2(1+\nu)(1-\nu)}\nabla(\nabla\cdot\Delta\mathbf{u}) \quad (1)$$

955 where E is the elastic modulus of the material (13.7 kPa here), and ν
956 is the Poisson ratio (0.49 for our CY elastomer substrate). Then, the
957 modulus of the projection of the traction force \mathbf{F} onto the xy plane is

$$958 \quad F_{xy} = \sqrt{F_x^2 + F_y^2} \quad (2)$$

959 Traditionally, F_{xy} is expressed in kPa (0.001 N/mm²) to be
960 subsequently multiplied by the area of each pixel (0.16 μm^2 for xy -
961 inspection images, while 0.01 μm^2 for xyz -inspection images due to
962 the better objective on the xyz -inspection setup).

963 Additionally, a filter step is incorporated into the analysis to extract
964 the pixels of the actually deformed regions with a mask to subtract the
965 noise. In this step, we utilize both images of the rest of the state and
966 the contracted state of hiPSC-CMs as a reference. A threshold of 0.3
967 \times the standard deviation of the contracted state of hiPSC-CMs was
968 added to the background recorded at the rest of the state of hiPSC-
969 CMs for each pixel. Pixels below this threshold were excluded in the
970 final mask (black pixels in Figure S1.a). The final mask generated was
971 then projected onto the raw traction force map. The corresponding
972 force profile of each pixel in the masked map was preserved for the
973 extraction of peak amplitudes and timing (Figure S1.a).

974 The mean of these force profiles (pixels within the masked traction
975 force map) was then defined as the force profiles of the hiPSC-CMs
976 within the field of the view, and a peak-detection algorithm (modified
977 based on the find peaks function (scipy, python)) was applied to
978 output the peak time points and contractility indications such as peak
979 amplitude, beat duration, and interpeak time (Figure S1.b). The peak
980 time point of each pixel (within the masked traction force map and
981 within the beat) was extracted (Figure S1.e). Then these time points
982 were subtracted from the earliest peak time point, yielding values that
983 begin with 0 and end with a threshold (0.3 s for healthy hiPSC-CMs,
984 0.4 s for diseased hiPSC-CMs). These differences are defined in this
985 study as latency values, and the distribution of the latency values can
986 be plotted in a line plot, with latency time as the x -axis and the
987 percentage of each latency value as the y -axis (Figure 2d). The latency
988 of each pixel can be presented on a latency map (Figure 2a,b, third
989 panel). The latency distributions could be further compared and
990 averaged between individual samples, and the center line is the mean
991 over different samples, and the gray zone covers all points within the
992 standard deviation (Figure 2f). The full-width half-maximum (fwhm)
993 of the mean latency distribution over different samples is extracted to
994 describe how spread the distribution is. The latency distribution is
995 referred to in this study as a delay and is used to compare the
996 efficiency of cell–cell mechanical communications between different
997 hiPSC-CMs configurations and cell lines.

998 **OPT_BF Data Analysis.** The OPT software was developed in
999 Matlab (Matlab 2023a, The Mathworks Inc., USA) and it was based
1000 on movement tracking with automatic feature detection relying on the
1001 Kanade-Lucas-Tomasi (KLT) algorithm,⁵² which is a recognized
1002 approach for feature extraction with the advantage of computational
1003 discharge.^{53,54} The whole batch of features returned by KLT was
1004 processed and filtered. The displacement of the selected features
1005 (green crosses in Figure 2b first panel) was calculated in x (dx_i) and y
1006 component (dy_i) for each feature i between time points 0 and t . The
1007 calibration factor to switch from the image reference system to the

actual contraction in physical units (μm) was calculated according to
the approach by Sala et al.⁴² The traction force in x,y is linearly
dependent on the displacement and inversely to the G matrix (eq
3).⁵⁵ The traction force was calculated from the Boussinesq equation,
under a small displacement assumption.⁵⁶

$$1013 \quad \mathbf{F} = G^{-1}\cdot[dx_i, dy_i, 0] \quad (3)$$

G matrix integrates the displacement with Young's modulus (E) and
the Poisson ratio ν of the substrate to which the hiPSC-CMs adhered
in the system, as hiPSC-CMs drag the substrate while contracting.⁵⁵

$$1017 \quad G_{\text{matrix}} = \begin{bmatrix} g_{11} & g_{12} & g_{13} \\ g_{21} & g_{22} & g_{23} \\ g_{31} & g_{32} & g_{33} \end{bmatrix} \quad (4)$$

Components within the G matrix are

$$1018 \quad g_{11} = \frac{1+\nu}{2\pi E} \cdot \left(\frac{2(1-\nu) \cdot \sqrt{d_x^2 + d_y^2}}{d_x^2 + d_y^2} + \frac{2\sqrt{d_x^2 + d_y^2} (\nu \cdot \sqrt{d_x^2 + d_y^2}) \cdot d_x^2}{(d_x^2 + d_y^2)^3} \right)$$

$$g_{21} = \frac{1+\nu}{2\pi E} \cdot \left(\frac{2\nu \cdot (d_x^2 + d_y^2) \cdot d_x d_y}{(d_x^2 + d_y^2)^3} \right)$$

$$g_{12} = g_{21}$$

$$g_{31} = \frac{1+\nu}{2\pi E} \cdot \left(\frac{(1-2\nu) \cdot d_x}{d_x^2 + d_y^2} \right)$$

$$g_{13} = -g_{31}$$

$$g_{22} = \frac{1+\nu}{2\pi E} \cdot \left(\frac{2(1-\nu) \cdot \sqrt{d_x^2 + d_y^2}}{d_x^2 + d_y^2} + \frac{2\sqrt{d_x^2 + d_y^2} (\nu \cdot \sqrt{d_x^2 + d_y^2}) \cdot d_y^2}{(d_x^2 + d_y^2)^3} \right)$$

$$g_{32} = \frac{1+\nu}{2\pi E} \cdot \left(\frac{(1-2\nu) \cdot d_y}{d_x^2 + d_y^2} \right)$$

$$g_{23} = -g_{32}$$

$$g_{33} = \frac{1+\nu}{2\pi E} \cdot \frac{2(1-\nu)}{\sqrt{d_x^2 + d_y^2}} \quad (5)$$

Detected features within the traction force map underwent the same
peak detection algorithm and the extraction of the peak time points,
which was used later to output latency values. They can be further
visualized in the latency map and latency distribution as cTFM.

1024 **HD-MEA Data Analysis.** In both whole-chip and zoom-in
1025 recordings of the hiPSC-CMs, the eCAP at each electrode was
1026 acquired and analyzed. From the profile of each eCAP, which is the
1027 eCAP plotted over time, the maximum absolute amplitude, the
1028 frequency of eCAP, and the time point of the absolute maximum
1029 amplitude (time stamp of this eCAP) were extracted (Figure S6.f,
1030 dashed lines). The maximum amplitude and the frequency of eCAP
1031 were plotted at each electrode location, generating the spatial
1032 amplitude and frequency maps (Figure 3f–h). The whole chip
1033 amplitude maps of the hiPSC-CMs on the HD-MEA were generated
1034 by subsequently routing 25 different electrode configurations,

1035 recording for 30 s for each configuration, and then stitching all results
 1036 together. The latency maps were derived from the time stamps of
 1037 ecAP recorded on each electrode. The first occurrence of a spike
 1038 event (the first time stamp) within a contraction (all electrodes
 1039 averaged in the field of view) can be found thanks to the high
 1040 temporal resolution of the recording system (50 μ s). Assigning this
 1041 earliest spike event as time 0, the relative latency time on other active
 1042 electrodes can be mapped (Figure 3g,h third panel) This approach
 1043 yields latency maps with vectors indicating the direction of the ecAP
 1044 flow. This process of analyzing time stamps and assigning them
 1045 spatially was based on a previously developed software package:
 1046 *Neuroflow*.^{65,89} Subsequently, these latency values recorded at all
 1047 electrodes can be extracted, and their probability can be visualized as a
 1048 latency distribution (Figure S6.d,e). We performed two whole-chip
 1049 recordings for CTRL and BRU hiPSC-CMs, and one whole-chip
 1050 recording for DCM, ISOGEN. Within the whole chip recordings of
 1051 CTRL and BRU, at least 5 zoomed-in recordings were acquired.

1052 **Statistical Analysis for the xy-Inspection.** One recording (at
 1053 least 1 min recording) from one sample seeded at a certain date was
 1054 considered as an “independent” sample, on which several (from 10 to
 1055 20) 200 \times 200 μ m² regions were imaged contributing to the mean
 1056 values for that sample. The number of biologically independent
 1057 experiments, i.e. of samples seeded at different substrates and at
 1058 different dates, was indicated as *N* in the caption or the text of each
 1059 figure. The number of independent experiments analyzed for each
 1060 condition were as follows: CTRL bilayer: 4, CTRL monolayer: 4,
 1061 BRU monolayer: 4, BRU bilayer: 4, DCM monolayer: 4, DCM
 1062 bilayer: 4, and Isogenic DCM bilayer: 3. Each sample had a paired
 1063 spontaneous and isoproterenol-stimulated result. These numbers are
 1064 also reported in the figure captions. The statistical tests were
 1065 performed using a home-built Python script. The Shapiro-Wilk test
 1066 was used to evaluate the normality of the data. For normally
 1067 distributed data, the *t*-test was performed. For data with several groups
 1068 (diseased states), the one-way ANOVA with pairwise Tukey multiple
 1069 comparisons test was performed. For all tests, a specificity of 0.05 was
 1070 set. In all box plots, the population median was indicated as a
 1071 horizontal line inside the boxplot. The box covers the first quartile to
 1072 the third quartile of the data. The whiskers extend from the box to the
 1073 farthest data point lying within 1.5 \times the interquartile range from the
 1074 box. Scattered dots are each experimental data point, outliers are
 1075 marked as diamonds (n.s. stands for not significant, * *p* < 0.05, ** *p* <
 1076 0.001, *** *p* < 0.0001, **** *p* < 0.00001, ***** *p* < 0.00001).

1077 The latency distributions were averaged over independent samples
 1078 and were plotted as latency time versus probability as a percentage of
 1079 that latency. The standard deviation above and below the mean was
 1080 indicated with a gray zone.

1081 ASSOCIATED CONTENT

1082 Data Availability Statement

1083 X.Z. and M.B. contributed equally to this work.

1084 SI Supporting Information

1085 The Supporting Information is available free of charge at
 1086 <https://pubs.acs.org/doi/10.1021/acsnano.4c03896>.

1087 Raw data (hiPSC-CM beating -treated with isoproter-
 1088 enol- in both QDs and BF channel) and processed data
 1089 (inferred by both cTFM -force video and latency map-
 1090 and OPT_BF images) (MP4)

1091 Processed data, ecAP propagation of a hiPSC-CM
 1092 bilayer on a HD-MEA (MP4)

1093 Figure S1: derivation of force maps from cTFM images
 1094 during hiPSC-CM contraction; Figure S2: OPT stability
 1095 against various brightness; Figure S3: electrical excit-
 1096 ability and connectivity of hiPSC-CM bilayers; Figure
 1097 S4: force profile characteristics and correlation between
 1098 cTFM and OPT_BF; Figure S5: xyz-inspection at
 1099 different locations of hiPSC-CM layers; Figure S6:
 1100 electrical quantification of hiPSC-CMs; Figure S7: xy-

1101 inspections of diseased cell lines in monolayer
 1102 configuration; Figure S8: electrical recordings of
 1103 diseased cell lines; Figure S9: Local electrical response
 1104 of CTRL and BRU hiPSC-CMs to isoproterenol; Table
 1105 S1: mechanical methods comparison in quantifying
 1106 single and layered CM contractility; and Table S2:
 1107 electrical recording methods comparison of CM (PDF)

AUTHOR INFORMATION

Corresponding Authors

Michele Miragoli – Laboratory of Applied Medical
 Technologies, Department of Medicine, University of Parma,
 43126 Parma, Italy; Humanitas Research Hospital —
 IRCCS, 20089 Rozzano, Italy; Email: michele.miragoli@unipr.it

Tomaso Zambelli – Laboratory of Biosensors and
 Bioelectronics, Institute for Biomedical Engineering, ETH
 Zürich, 8092 Zürich, Switzerland; orcid.org/0000-0003-0965-0950; Email: ztomaso@ethz.ch

Authors

Xinyu Zhang – Laboratory of Biosensors and Bioelectronics,
 Institute for Biomedical Engineering, ETH Zürich, 8092
 Zürich, Switzerland; orcid.org/0000-0002-7762-0991

Margherita Burattini – Laboratory of Applied Medical
 Technologies, Department of Medicine, University of Parma,
 43126 Parma, Italy; Department of Maternity, Surgery and
 Dentistry, University of Verona, 37134 Verona, Italy;
orcid.org/0000-0002-6899-5791

Jens Duru – Laboratory of Biosensors and Bioelectronics,
 Institute for Biomedical Engineering, ETH Zürich, 8092
 Zürich, Switzerland

Nafsika Chala – Laboratory of Thermodynamics in Emerging
 Technologies, Department of Mechanical and Process
 Engineering, ETH Zürich, 8092 Zurich, Switzerland;
orcid.org/0000-0002-2293-6585

Nino Wyssen – Laboratory of Biosensors and Bioelectronics,
 Institute for Biomedical Engineering, ETH Zürich, 8092
 Zürich, Switzerland

”Carla Cofino Fabres – Department of Applied Stem Cell
 Technologies, TechMed Centre, University of Twente, 7500
 AE Enschede, The Netherland

Jose Manuel Rivera Arbelaez – Department of Applied Stem
 Cell Technologies, TechMed Centre, University of Twente,
 7500 AE Enschede, The Netherland; orcid.org/0000-0002-0075-6006

Robert Passier – Department of Applied Stem Cell
 Technologies, TechMed Centre, University of Twente, 7500
 AE Enschede, The Netherland

Dimos Poulikakos – Laboratory of Thermodynamics in
 Emerging Technologies, Department of Mechanical and
 Process Engineering, ETH Zürich, 8092 Zurich, Switzerland;
orcid.org/0000-0001-5733-6478

Aldo Ferrari – Laboratory of Thermodynamics in Emerging
 Technologies, Department of Mechanical and Process
 Engineering, ETH Zürich, 8092 Zurich, Switzerland;
 Experimental Continuum Mechanics, EMPA, Swiss Federal
 Laboratories for Material Science and Technologies, 8600
 Dübendorf, Switzerland

Christina Tringides – Laboratory of Biosensors and
 Bioelectronics, Institute for Biomedical Engineering, ETH
 Zürich, 8092 Zürich, Switzerland

1161 János Vörös – Laboratory of Biosensors and Bioelectronics,
1162 Institute for Biomedical Engineering, ETH Zürich, 8092
1163 Zürich, Switzerland; orcid.org/0000-0001-6054-6230
1164 Giovanni Battista Luciani – Department of Maternity,
1165 Surgery and Dentistry, University of Verona, 37134 Verona,
1166 Italy

1167 Complete contact information is available at:
1168 <https://pubs.acs.org/10.1021/acsnano.4c03896>

1169 Notes

1170 The authors declare no competing financial interest.

1171 ACKNOWLEDGMENTS

1172 X.Z. was supported by the EU H2020 Marie Skłodowska-Curie
1173 Action (ITN “SENTINEL” no. 812398 to T.Z.). M.B. was
1174 supported by the Scientific Exchange Grants program of the
1175 European Molecular Biology Organization (EMBO, grant no.
1176 10207). J.D. was supported by the Swiss National Science
1177 Foundation (SNSF no. 182779 to J.V.). M.M. was supported
1178 by the University of Parma through the action “BANDO YIRG
1179 UNIPR” co-funded by MUR-Italian Ministry of Universities
1180 and Research - D.M. 737/2021 and by PNR - PNRR –
1181 NextGenerationEU and National Recovery and Resilience Plan
1182 (NRRP), Mission 4 Component 2 Investment 1.5 - Call for
1183 tender No.3277 of 30/12/2021 of Italian Ministry of
1184 University and Research funded by the European Union –
1185 NextGenerationEU (no. ECS00000033, Ecosister) and “FIL-
1186 Quota Incentivante” of University of Parma and cosponsored
1187 by Fondazione Cariparma.

1188 REFERENCES

1189 (1) Roth, G. A.; Mensah, G. A.; Johnson, C. O. Global Burden of
1190 Cardiovascular Diseases and Risk Factors, 1990–2019. *J. Am. Coll.*
1191 *Cardiol.* **2020**, *76*, 2982–3021.
1192 (2) Vagnozzi, R. J.; Molkenkin, J. D.; Houser, S. R. New Myocyte
1193 Formation in the Adult Heart. *Circ. Res.* **2018**, *123*, 159–176.
1194 (3) Vuorenmaa, H.; Björninen, M.; Välimäki, H.; Ahola, A.; Kroon,
1195 M.; Honkamäki, L.; Koivumäki, J. T.; Pekkanen-Mattila, M. Building
1196 blocks of microphysiological system to model physiology and
1197 pathophysiology of human heart. *Front. Physiol.* **2023**, *14*,
1198 No. 1213959.
1199 (4) Quinn, T. A.; Kohl, P. Cardiac Mechano-Electric Coupling:
1200 Acute Effects of Mechanical Stimulation on Heart Rate and Rhythm.
1201 *Physiol. Rev.* **2021**, *101*, 37–92.
1202 (5) Bers, D. M. Cardiac excitation-contraction coupling. *Nature*
1203 **2002**, *415*, 198–205.
1204 (6) Rohr, S.; Kucera, J. P.; Fast, V. G.; Kléber, A. G. Paradoxical
1205 Improvement of Impulse Conduction in Cardiac Tissue by Partial
1206 Cellular Uncoupling. *Science* **1997**, *275*, 841–844.
1207 (7) Li, K. H. C.; Lee, S.; Yin, C.; Liu, T.; Ngarmukos, T.; Conte, G.;
1208 Yan, G.-X.; Sy, R. W.; Letsas, K. P.; Tse, G. Brugada syndrome: A
1209 comprehensive review of pathophysiological mechanisms and risk
1210 stratification strategies. *IJC Heart & Vasculature* **2020**, *26*,
1211 No. 100468.
1212 (8) Tse, G.; Liu, T.; Li, K. H. C.; Laxton, V.; Chan, Y. W. F.; Keung,
1213 W.; Li, R. A.; Yan, B. P. Electrophysiological Mechanisms of Brugada
1214 Syndrome: Insights from Pre-clinical and Clinical Studies. *Front.*
1215 *Physiol.* **2016**, *7*, 467.
1216 (9) Clippinger, S. R.; Cloonan, P. E.; Greenberg, L.; Ernst, M.;
1217 Stump, W. T.; Greenberg, M. J. Disrupted mechanobiology links the
1218 molecular and cellular phenotypes in familial dilated cardiomyopathy.
1219 *Proc. Natl. Acad. Sci. U. S. A.* **2019**, *116*, 17831–17840.
1220 (10) McNally, E. M.; Mestroni, L. Dilated Cardiomyopathy. *Circ.*
1221 *Res.* **2017**, *121*, 731–748.

(11) Damluji, A. A.; van Diepen, S.; Katz, J. N.; Menon, V.; Tamis-
1222 Holland, J. E.; Bakitas, M.; Cohen, M. G.; Balsam, L. B.; Chikwe, J.;
1223 American Heart Association Council on Clinical Cardiology; Council
1224 on Arteriosclerosis, Thrombosis and Vascular Biology; Council on
1225 Cardiovascular Surgery and Anesthesia; Council on Cardiovascular
1226 and Stroke Nursing. Mechanical Complications of Acute Myocardial
1227 Infarction: A Scientific Statement From the American Heart
1228 Association. *Circulation* **2021**, *144*, e16–e35.
1229 (12) Jia, B. Z.; Qi, Y.; Wong-Campos, J. D.; Megason, S. G.; Cohen,
1230 A. E. A bioelectrical phase transition patterns the first vertebrate
1231 heartbeats. *Nature* **2023**, *622*, 149–155.
1232 (13) Losurdo, P.; Stolfo, D.; Merlo, M.; Barbati, G.; Gobbo, M.;
1233 Gigli, M.; Ramani, F.; Pinamonti, B.; Zecchin, M.; Finocchiaro, G.;
1234 Mestroni, L.; Sinagra, G. Early Arrhythmic Events in Idiopathic
1235 Dilated Cardiomyopathy. *JACC: Clinical Electrophysiology* **2016**, *2*,
1236 535–543.
1237 (14) Rohr, S. Role of gap junctions in the propagation of the cardiac
1238 action potential. *Cardiovasc. Res.* **2004**, *62*, 309–322.
1239 (15) Sheehy, S. P.; Grosberg, A.; Parker, K. K. The contribution of
1240 cellular mechanotransduction to cardiomyocyte form and function.
1241 *Biomechanics and Modeling in Mechanobiology* **2012**, *11*, 1227–1239.
1242 (16) Kucera, J. P.; Rohr, S.; Rudy, Y. Localization of sodium
1243 channels in intercalated disks modulates cardiac conduction. *Circ. Res.*
1244 **2002**, *91*, 1176–1182.
1245 (17) Adams, W. P.; et al. Extracellular Perinexal Separation Is a
1246 Principal Determinant of Cardiac Conduction. *Circ. Res.* **2023**, *133*,
1247 658–673.
1248 (18) Schultz, F.; Swiatlowska, P.; Alvarez-Laviada, A.; Sanchez-
1249 Alonso, J. L.; Song, Q.; de Vries, A. A. F.; Pijnappels, D. A.; Ongstad,
1250 E.; Braga, V. M. M.; Entcheva, E.; Gourdie, R. G.; Miragoli, M.;
1251 Gorelik, J. Cardiomyocyte–myofibroblast contact dynamism is
1252 modulated by connexin-43. *FASEB J.* **2019**, *33*, 10453–10468.
1253 (19) Liu, Z.; Tan, J. L.; Cohen, D. M.; Yang, M. T.; Sniadecki, N. J.;
1254 Ruiz, S. A.; Nelson, C. M.; Chen, C. S. Mechanical tugging force
1255 regulates the size of cell–cell junctions. *Proc. Natl. Acad. Sci. U. S. A.*
1256 **2010**, *107*, 9944–9949.
1257 (20) Wang, N.; Butler, J. P.; Ingber, D. E. Mechanotransduction
1258 Across the Cell Surface and Through the Cytoskeleton. *Science* **1993**,
1259 *260*, 1124–1127.
1260 (21) Samarel, A. M. Costameres, focal adhesions, and cardiomyocyte
1261 mechanotransduction. *American Journal of Physiology-Heart and*
1262 *Circulatory Physiology* **2005**, *289*, H2291.
1263 (22) Yang, X.; Pabon, L.; Murry, C. E. Engineering Adolescence.
1264 *Circ. Res.* **2014**, *114*, 511–523.
1265 (23) Devalla, H. D.; Passier, R. Cardiac differentiation of pluripotent
1266 stem cells and implications for modeling the heart in health and
1267 disease. *Sci. Transl. Med.* **2018**, *10*, eaah5457.
1268 (24) Musunuru, K.; Sheikh, F.; Gupta, R. M.; Houser, S. R.; Maher,
1269 K. O.; Milan, D. J.; Terzic, A.; Wu, J. C.; American Heart Association
1270 Council on Functional Genomics and Translational Biology; Council
1271 on Cardiovascular Disease in the Young; Council on Cardiovascular
1272 and Stroke Nursing. Induced Pluripotent Stem Cells for Cardiovas-
1273 cular Disease Modeling and Precision Medicine: A Scientific
1274 Statement From the American Heart Association. *Circ. Gen. Precis.*
1275 *Med.* **2018**, *11*, No. e000043.
1276 (25) Li, J.; Hua, Y.; Miyagawa, S.; Zhang, J.; Li, L.; Liu, L.; Sawa, Y.
1277 hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug
1278 Discovery. *International Journal of Molecular Sciences* **2020**, *21*, 8893.
1279 (26) Liang, P.; Lan, F.; Lee, A. S.; Gong, T.; Sanchez-Freire, V.;
1280 Wang, Y.; Diecke, S.; Sallam, K.; Knowles, J. W.; Wang, P. J.; Nguyen,
1281 P. K.; Bers, D. M.; Robbins, R. C.; Wu, J. C. Drug Screening Using a
1282 Library of Human Induced Pluripotent Stem Cell-Derived Cardio-
1283 myocytes Reveals Disease Specific Patterns of Cardiotoxicity.
1284 *Circulation* **2013**, *127*, 1677–1691.
1285 (27) Dou, W.; Malhi, M.; Zhao, Q.; Wang, L.; Huang, Z.; Law, J.;
1286 Liu, N.; Simmons, C. A.; Maynes, J. T.; Sun, Y. Microengineered
1287 platforms for characterizing the contractile function of in vitro cardiac
1288 models. *Microsyst. Nanoeng.* **2022**, *8*, 26.
1289

- 1290 (28) Hayes, H. B.; Nicolini, A. M.; Arrowood, C. A.; Chvatal, S. A.;
1291 Wolfson, D. W.; Cho, H. C.; Sullivan, D. D.; Chal, J.; Fermi, B.;
1292 Clements, M.; Ross, J. D.; Millard, D. C. Novel method for action
1293 potential measurements from intact cardiac monolayers with
1294 multiwell microelectrode array technology. *Sci. Rep.* **2019**, *9*, 11893.
1295 (29) Gao, J.; Liao, C.; Liu, S.; Xia, T.; Jiang, G. Nanotechnology:
1296 new opportunities for the development of patch-clamps. *J. Nano-*
1297 *biotechnol.* **2021**, *19*, 97.
1298 (30) Dunlop, J.; Bowlby, M.; Peri, R.; Vasilyev, D.; Arias, R. High-
1299 throughput electrophysiology: an emerging paradigm for ion-channel
1300 screening and physiology. *Nat. Rev. Drug Discovery* **2008**, *7*, 358–368.
1301 (31) Obien, M. E. J.; Deligkaris, K.; Bullmann, T.; Bakkum, D. J.;
1302 Frey, U. Revealing neuronal function through microelectrode array
1303 recordings. *Front. Neurosci.* **2015**, *8*, 423.
1304 (32) Ballini, M.; et al. A 1024-Channel CMOS Microelectrode Array
1305 With 26,400 Electrodes for Recording and Stimulation of Electrogenic
1306 Cells In Vitro. *IEEE journal of solid-state circuits* **2014**, *49*, 2705–2719.
1307 (33) Dragas, J.; Viswam, V.; Shadmani, A.; Chen, Y.; Bounik, R.;
1308 Stettler, A.; Radivojevic, M.; Geissler, S.; Obien, M.; Müller, J.;
1309 Hierlemann, A. A Multi-Functional Microelectrode Array Featuring
1310 59760 Electrodes, 2048 Electrophysiology Channels, Stimulation,
1311 Impedance Measurement and Neurotransmitter Detection Channels.
1312 *IEEE journal of solid-state circuits* **2017**, *52*, 1576–1590.
1313 (34) Lee, J.; Gänswein, T.; Ulsan, H.; Emmenegger, V.; Saguner, A.
1314 M.; Duru, F.; Hierlemann, A. Repeated and On-Demand Intracellular
1315 Recordings of Cardiomyocytes Derived from Human-Induced
1316 Pluripotent Stem Cells. *ACS Sensors* **2022**, *7*, 3181–3191.
1317 (35) Ferrari, A. Recent technological advancements in traction force
1318 microscopy. *Biophysical Reviews* **2019**, *11*, 679–681.
1319 (36) Sabass, B.; Gardel, M. L.; Waterman, C. M.; Schwarz, U. S.
1320 High Resolution Traction Force Microscopy Based on Experimental
1321 and Computational Advances. *Biophys. J.* **2008**, *94*, 207–220.
1322 (37) Colin-York, H.; Shrestha, D.; Felce, J. H.; Waithe, D.;
1323 Moeendarbary, E.; Davis, S. J.; Eggeling, C.; Fritzsche, M. Super-
1324 Resolved Traction Force Microscopy (STFM). *Nano Lett.* **2016**, *16*,
1325 2633–2638.
1326 (38) Laurila, E.; Ahola, A.; Hyttinen, J.; Aalto-Setälä, K. Methods for
1327 in vitro functional analysis of iPSC derived cardiomyocytes — Special
1328 focus on analyzing the mechanical beating behavior. *Biochimica et*
1329 *Biophysica Acta (BBA) - Molecular Cell Research* **2016**, *1863*, 1864–
1330 1872.
1331 (39) Huang, Y.; Schell, C.; Huber, T. B.; Şimşek, A. N.; Hersch, N.;
1332 Merkel, R.; Gompper, G.; Sabass, B. Traction force microscopy with
1333 optimized regularization and automated Bayesian parameter selection
1334 for comparing cells. *Sci. Rep.* **2019**, *9*, 539.
1335 (40) Ribeiro, M. C.; Tertoolen, L. G.; Guadix, J. A.; Bellin, M.;
1336 Kosmidis, G.; D'Aniello, C.; Monshouwer-Kloots, J.; Goumans, M.-J.;
1337 Wang, Y.-L.; Feinberg, A. W.; Mummery, C. L.; Passier, R. Functional
1338 maturation of human pluripotent stem cell derived cardiomyocytes in
1339 vitro – Correlation between contraction force and electrophysiology.
1340 *Biomaterials* **2015**, *51*, 138–150.
1341 (41) Czirok, A.; Isai, D. G.; Kosa, E.; Rajasingh, S.; Kinsey, W.;
1342 Neufeld, Z.; Rajasingh, J. Optical-flow based non-invasive analysis of
1343 cardiomyocyte contractility. *Sci. Rep.* **2017**, *7*, 10404.
1344 (42) Sala, L.; et al. Musclemotion: A Versatile Open Software Tool
1345 to Quantify Cardiomyocyte and CardiacMuscle Contraction In Vitro
1346 and In Vivo. *Circ. Res.* **2018**, *122*, e5–e16.
1347 (43) Frotscher, R.; Muanghong, D.; Dursun, G.; Goßmann, M.;
1348 Temiz-Artmann, A.; Staat, M. Sample-specific adaption of an
1349 improved electro-mechanical model of in vitro cardiac tissue. *J.*
1350 *Biomech.* **2016**, *49*, 2428–2435.
1351 (44) McCain, M. L.; Agarwal, A.; Nesmith, H. W.; Nesmith, A. P.;
1352 Parker, K. K. Micromolded gelatin hydrogels for extended culture of
1353 engineered cardiac tissues. *Biomaterials* **2014**, *35*, 5462–5471.
1354 (45) Bergert, M.; Lendenmann, T.; Zündel, M.; Ehret, A. E.;
1355 Panozzo, D.; Richner, P.; Kim, D. K.; Kress, S. J. P.; Norris, D. J.;
1356 Sorkine-Hornung, O.; Mazza, E.; Poulidakos, D.; Ferrari, A. Confocal
1357 reference free traction force microscopy. *Nat. Commun.* **2016**, *7*,
1358 No. 12814.
(46) Meister, A.; Gabi, M.; Behr, P.; Studer, P.; Vörös, J.; 1359
Niedermann, P.; Bitterli, J.; Polesel-Maris, J.; Liley, M.; 1360
Heinzlmann, H.; Zambelli, T. FluidFM: Combining Atomic Force 1361
Microscopy and Nanofluidics in a Universal Liquid Delivery System 1362
for Single Cell Applications and Beyond. *Nano Lett.* **2009**, *9*, 2501– 1363
2507. 1364
(47) Li, M.; Liu, L.; Zambelli, T. FluidFM for single-cell biophysics. 1365
Nano Research **2022**, *15*, 773–786. 1366
(48) Kress, S. J. P.; Antolinez, F. V.; Richner, P.; Jayanti, S. V.; Kim, 1367
D. K.; Prins, F.; Riedinger, A.; Fischer, M. P. C.; Meyer, S.; McPeak, 1368
K. M.; Poulidakos, D.; Norris, D. J. Wedge Waveguides and 1369
Resonators for Quantum Plasmonics. *Nano Lett.* **2015**, *15*, 6267– 1370
6275. 1371
(49) Nguyen, D. T.; Nagarajan, N.; Zorlutuna, P. Effect of Substrate 1372
Stiffness on Mechanical Coupling and Force Propagation at the 1373
Infarct Boundary. *Biophys. J.* **2018**, *115*, 1966–1980. 1374
(50) Pfeiffer, E. R.; Tangney, J. R.; Omens, J. H.; McCulloch, A. D. 1375
Biomechanics of Cardiac Electromechanical Coupling and Mechano- 1376
electric Feedback. *J. Biomech. Eng.* **2014**, *136*, No. 021007. 1377
(51) Lendenmann, T.; Schneider, T.; Dumas, J.; Tarini, M.; 1378
Giampietro, C.; Bajpai, A.; Chen, W.; Gerber, J.; Poulidakos, D.; 1379
Ferrari, A.; Panozzo, D. Cellogram: On-the-Fly Traction Force 1380
Microscopy. *Nano Lett.* **2019**, *19*, 6742–6750. 1381
(52) Lucas, B. D.; Kanade, T. An iterative image registration 1382
technique with an application to stereo vision. *Proceedings of the 7th* 1383
International Joint Conference on Artificial Intelligence 1981, *2*, 674– 1384
679. 1385
(53) Wu, H.; Sankaranarayanan, A. C.; Chellappa, R. Online 1386
Empirical Evaluation of Tracking Algorithms. *IEEE Trans. Pattern* 1387
Anal. Mach. Intell. **2010**, *32*, 1443–1458. 1388
(54) Sharma, P.; Kokare, P. M.; Kolekar, M. H. *Recent Trends in* 1389
Communication, Computing, and Electronics; Lecture Notes in Electrical 1390
Engineering; Springer: Singapore, 2019; 323–331. 1391
(55) Dembo, M.; Wang, Y.-L. Stresses at the Cell-to-Substrate 1392
Interface during Locomotion of Fibroblasts. *Biophys. J.* **1999**, *76*, 1393
2307–2316. 1394
(56) Schwarz, U. S.; Soiné, J. R. D Traction force microscopy on soft 1395
elastic substrates: A guide to recent computational advances. 1396
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research **2015**, 1397
1853, 3095–3104. 1398
(57) Oria, R.; Wiegand, T.; Escribano, J.; Elosegui-Artola, A.; 1399
Uriarte, J. J.; Moreno-Pulido, C.; Platzman, I.; Delcanale, P.; 1400
Albertazzi, L.; Navajas, D.; Trepach, X.; García-Aznar, J. M.; 1401
Cavalcanti-Adam, E. A.; Roca-Cusachs, P. Force loading explains 1402
spatial sensing of ligands by cells. *Nature* **2017**, *552*, 219–224. 1403
(58) Ito, M.; Nomura, S.; Morita, H.; Komuro, I. Trends and 1404
Limitations in the Assessment of the Contractile Properties of Human 1405
Induced Pluripotent Stem Cell-Derived Cardiomyocytes From 1406
Patients With Dilated Cardiomyopathy. *Front. Cardiovasc. Med.* 1407
2020, *7*, 154. 1408
(59) Stoppel, W. L.; Kaplan, D. L.; Black, L. D. Electrical and 1409
mechanical stimulation of cardiac cells and tissue constructs. *Adv.* 1410
Drug Delivery Rev. **2016**, *96*, 135–155. 1411
(60) Tulloch, N. L.; Muskheli, V.; Razumova, M. V.; Korte, F. S.; 1412
Regnier, M.; Hauch, K. D.; Pabon, L.; Reinecke, H.; Murry, C. E. 1413
Growth of Engineered Human Myocardium With Mechanical 1414
Loading and Vascular Coculture. *Circ. Res.* **2011**, *109*, 47–59. 1415
(61) Chala, N.; Zhang, X.; Zambelli, T.; Zhang, Z.; Schneider, T.; 1416
Panozzo, D.; Poulidakos, D.; Ferrari, A. 4D Force Detection of Cell 1417
Adhesion and Contractility. *Nano Lett.* **2023**, *23*, 2467–2475. 1418
(62) Liu, J.; Sun, N.; Bruce, M. A.; Wu, J. C.; Butte, M. J.; Muller, D. 1419
J. Atomic Force Mechanobiology of Pluripotent Stem Cell-Derived 1420
Cardiomyocytes. *PLoS One* **2012**, *7*, No. e37559. 1421
(63) Yasuda, K. Dominant rule of community effect in synchronized 1422
beating behavior of cardiomyocyte networks. *Biophysical Reviews* 1423
2020, *12*, 481–501. 1424
(64) Asai, Y.; Tada, M.; Otsuji, T. G.; Nakatsuji, N. Combination of 1425
functional cardiomyocytes derived from human stem cells and a 1426
highly-efficient microelectrode array system: an ideal hybrid model 1427

- 1428 assay for drug development. *Curr. Stem Cell Res. Ther.* **2010**, *5*, 227–
1429 232.
- 1430 (65) Duru, J.; Kuchler, J.; Ihle, S. J.; Forró, C.; Bernardi, A.;
1431 Girardin, S.; Hengstler, J.; Wheeler, S.; Vörös, J.; Ruff, T. Engineered
1432 Biological Neural Networks on High Density CMOS Microelectrode
1433 Arrays. *Frontiers in Neuroscience* **2022**, *16*, No. 829884.
- 1434 (66) Bouten, C. V.; Cheng, C.; Vermue, I. M.; Gawlitta, D.; Passier,
1435 R. Cardiovascular Tissue Engineering and Regeneration: A Plea for
1436 Further Knowledge Convergence. *Tissue Engineering Part A* **2022**, *28*,
1437 525–541.
- 1438 (67) Reyes Lua, A. M.; Hopf, R.; Mazza, E. Factors influencing the
1439 mechanical properties of soft elastomer substrates for traction force
1440 microscopy. *Mech. Soft Mater.* **2020**, *2*, 6.
- 1441 (68) Wells, S. P.; Waddell, H. M.; Sim, C. B.; Lim, S. Y.; Bernasochi,
1442 G. B.; Pavlovic, D.; Kirchhof, P.; Porrello, E. R.; Delbridge, L. M. D.;
1443 Bell, J. R. Cardiomyocyte functional screening: interrogating
1444 comparative electrophysiology of high-throughput model cell systems.
1445 *American Journal of Physiology-Cell Physiology* **2019**, *317*, C1256–
1446 C1267.
- 1447 (69) Fang, J.; Wei, X.; Li, H.; Hu, N.; Liu, X.; Xu, D.; Zhang, T.;
1448 Wan, H.; Wang, P.; Xie, X. Cardiomyocyte electrical-mechanical
1449 synchronized model for high-content, dose-quantitative and time-
1450 dependent drug assessment. *Microsyst. Nanoeng.* **2021**, *7*, 26.
- 1451 (70) Liu, W.; Han, J. L.; Tomek, J.; Bub, G.; Entcheva, E.
1452 Simultaneous Widefield Voltage and Dye-Free Optical Mapping
1453 Quantifies Electromechanical Waves in Human Induced Pluripotent
1454 Stem Cell-Derived Cardiomyocytes. *ACS Photonics* **2023**, *10*, 1070–
1455 1083.
- 1456 (71) Ross, S. A.; Wakeling, J. M. Muscle shortening velocity depends
1457 on tissue inertia and level of activation during submaximal
1458 contractions. *Biology Letters* **2016**, *12*, No. 20151041.
- 1459 (72) Hall, C.; Gehmlich, K.; Denning, C.; Pavlovic, D. Complex
1460 Relationship Between Cardiac Fibroblasts and Cardiomyocytes in
1461 Health and Disease. *J. Am. Heart Assoc.* **2021**, *10*, No. e019338.
- 1462 (73) Ribeiro, M. C.; Slaats, R. H.; Schwach, V.; Rivera-Arbelaez, J.
1463 M.; Tertoolen, L. G. J.; van Meer, B. J.; Molenaar, R.; Mummery, C.
1464 L.; Claessens, M. M. A. E.; Passier, R. A cardiomyocyte show of force:
1465 A fluorescent alpha-actinin reporter line sheds light on human
1466 cardiomyocyte contractility versus substrate stiffness. *Journal of*
1467 *Molecular and Cellular Cardiology* **2020**, *141*, 54–64.
- 1468 (74) McCain, M. L.; Lee, H.; Aratyn-Schaus, Y.; Kléber, A. G.;
1469 Parker, K. K. Cooperative coupling of cell-matrix and cell–cell
1470 adhesions in cardiac muscle. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*,
1471 9881–9886.
- 1472 (75) Pires, R. H.; Shree, N.; Manu, E.; Guźniczak, E.; Otto, O.
1473 Cardiomyocyte mechanodynamics under conditions of actin remodel-
1474 ling. *Philosophical Transactions of the Royal Society B: Biological*
1475 *Sciences* **2019**, *374*, No. 20190081.
- 1476 (76) Shah, K.; Seeley, S.; Schulz, C.; Fisher, J.; Gururaja Rao, S.
1477 Calcium Channels in the Heart: Disease States and Drugs. *Cells* **2022**,
1478 *11*, 943.
- 1479 (77) de Boer, T.; van Rijen, H.; van der Heyden, M.; de Bakker, J.;
1480 van Veen, T. Adrenergic regulation of conduction velocity in cultures
1481 of immature cardiomyocytes. *Netherlands Heart Journal* **2008**, *16*,
1482 106–109.
- 1483 (78) Kim, J. J.; Yang, L.; Lin, B.; Zhu, X.; Sun, B.; Kaplan, A. D.;
1484 Bett, G. C.; Rasmusson, R. L.; London, B.; Salama, G. Mechanism of
1485 automaticity in cardiomyocytes derived from human induced
1486 pluripotent stem cells. *Journal of molecular and cellular cardiology*
1487 **2015**, *81*, 81–93.
- 1488 (79) Wang, H.-W.; Yang, Z.-F.; Zhang, Y.; Yang, J.-M.; Liu, Y.-M.;
1489 Li, C.-Z. Beta-receptor activation increases sodium current in guinea
1490 pig heart. *Acta Pharmacologica Sinica* **2009**, *30*, 1115–1122.
- 1491 (80) Sheehy, S. P.; Grosberg, A.; Qin, P.; Behm, D. J.; Ferrier, J. P.;
1492 Eagleson, M. A.; Nesmith, A. P.; Krull, D.; Falls, J. G.; Campbell, P.
1493 H.; McCain, M. L.; Willette, R. N.; Hu, E.; Parker, K. K. Toward
1494 improved myocardial maturity in an organ-on-chip platform with
1495 immature cardiac myocytes. *Experimental Biology and Medicine* **2017**,
1496 *242*, 1643–1656.
- (81) Ahmad, F. S.; Jin, Y.; Grassam-Rowe, A.; Zhou, Y.; Yuan, M.; 1497
Fan, X.; Zhou, R.; Mu-u-min, R.; O'Shea, C.; Ibrahim, A. M.; Hyder, 1498
W.; Aguib, Y.; Yacoub, M.; Pavlovic, D.; Zhang, Y.; Tan, X.; Lei, M.; 1499
Terrar, D. A.; et al. Generation of cardiomyocytes from human- 1500
induced pluripotent stem cells resembling atrial cells with ability to 1501
respond to adrenoceptor agonists. *Philos. Trans. R. Soc. Lond. Ser. B,* 1502
Biol. Sci. **2023**, *378*, No. 20220312. 1503
- (82) Ernst, P.; Bidwell, P. A.; Dora, M.; Thomas, D. D.; Kamdar, F. 1504
Cardiac calcium regulation in human induced pluripotent stem cell 1505
cardiomyocytes: Implications for disease modeling and maturation. 1506
Frontiers in Cell and Developmental Biology **2023**, *10*, No. 986107. 1507
- (83) Antzelevitch, C.; et al. Loss-of-Function Mutations in the 1508
Cardiac Calcium Channel Underlie a New Clinical Entity 1509
Characterized by ST-Segment Elevation, Short QT Intervals, and 1510
Sudden Cardiac Death. *Circulation* **2007**, *115*, 442–449. 1511
- (84) Westhoff, M.; Dixon, R. E. Mechanisms and Regulation of 1512
Cardiac CaV1.2 Trafficking. *International Journal of Molecular Sciences* 1513
2021, *22*, 5927. 1514
- (85) Sader, J. E.; Sanelli, J. A.; Adamson, B. D.; Monty, J. P.; Wei, X.; 1515
Crawford, S. A.; Friend, J. R.; Marusic, I.; Mulvaney, P.; Bieske, E. J. 1516
Spring constant calibration of atomic force microscope cantilevers of 1517
arbitrary shape. *Rev. Sci. Instrum.* **2012**, *83*, 103705. 1518
- (86) Helfricht, N.; Mark, A.; Dorwling-Carter, L.; Zambelli, T.; 1519
Papastavrou, G. Extending the limits of direct force measurements: 1520
colloidal probes from sub-micron particles. *Nanoscale* **2017**, *9*, 9491– 1521
9501. 1522
- (87) Bonyar, A.; Nagy, G.; Guntheimer, H.; Fläschner, G.; Horvath, 1523
R. Hydrodynamic function and spring constant calibration of 1524
FluidFM micropipette cantilevers. *Microsyst. Nanoeng.* **2024**, *10*, 26. 1525
- (88) Sittl, S.; Helfricht, N.; Papastavrou, G. Contactless calibration 1526
of microchanneled AFM cantilevers for fluidic force microscopy. 1527
VIEW **2024**, *5*, No. 20230063. 1528
- (89) Duru, J.; Maurer, B.; Giles Doran, C.; Jelitto, R.; Kuchler, J.; 1529
Ihle, S. J.; Ruff, T.; John, R.; Genocchi, B.; Vörös, J. Investigation of 1530
the input-output relationship of engineered neural networks using 1531
high-density microelectrode arrays. *Biosens. Bioelectron.* **2023**, *239*, 1532
No. 115591. 1533